Movatterモバイル変換


[0]ホーム

URL:


US5446090A - Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules - Google Patents

Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
Download PDF

Info

Publication number
US5446090A
US5446090AUS08/151,481US15148193AUS5446090AUS 5446090 AUS5446090 AUS 5446090AUS 15148193 AUS15148193 AUS 15148193AUS 5446090 AUS5446090 AUS 5446090A
Authority
US
United States
Prior art keywords
sub
sulfone
moiety
poly
ethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/151,481
Inventor
J. Milton Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Shearwater Polymers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater Polymers IncfiledCriticalShearwater Polymers Inc
Priority to US08/151,481priorityCriticalpatent/US5446090A/en
Assigned to SHEARWATER POLYMERS, INC.reassignmentSHEARWATER POLYMERS, INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: HARRIS, J. MILTON
Priority to EP01122161Aprioritypatent/EP1176160A3/en
Priority to NZ276313Aprioritypatent/NZ276313A/en
Priority to BR9408048Aprioritypatent/BR9408048A/en
Priority to UA96062250Aprioritypatent/UA58481C2/en
Priority to JP07514031Aprioritypatent/JP3114998B2/en
Priority to ES95901226Tprioritypatent/ES2173943T3/en
Priority to CA002176203Aprioritypatent/CA2176203C/en
Priority to PL94314298Aprioritypatent/PL180149B1/en
Priority to KR1019960702507Aprioritypatent/KR100225746B1/en
Priority to HU9601253Aprioritypatent/HU225649B1/en
Priority to RU96113123/04Aprioritypatent/RU2176253C2/en
Priority to SK608-96Aprioritypatent/SK284527B6/en
Priority to DE69430317Tprioritypatent/DE69430317T2/en
Priority to CZ19961375Aprioritypatent/CZ295640B6/en
Priority to RO96-00959Aprioritypatent/RO118434B1/en
Priority to AT95901226Tprioritypatent/ATE215577T1/en
Priority to CN94194460Aprioritypatent/CN1085689C/en
Priority to ROA200000307Aprioritypatent/RO121855B1/en
Priority to AU10548/95Aprioritypatent/AU687937B2/en
Priority to DK95901226Tprioritypatent/DK0728155T3/en
Priority to EE9600128Aprioritypatent/EE03448B1/en
Priority to PCT/US1994/013013prioritypatent/WO1995013312A1/en
Priority to EP95901226Aprioritypatent/EP0728155B1/en
Priority to US08/473,734prioritypatent/US5739208A/en
Application grantedgrantedCritical
Publication of US5446090ApublicationCriticalpatent/US5446090A/en
Priority to BG100568Aprioritypatent/BG63399B1/en
Priority to NO19961918Aprioritypatent/NO315377B1/en
Priority to FI962004Aprioritypatent/FI117441B/en
Priority to US09/027,679prioritypatent/US5900461A/en
Priority to US09/294,188prioritypatent/US6610281B2/en
Assigned to SHEARWATER CORPORATIONreassignmentSHEARWATER CORPORATIONCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER POLYMERS, INC.
Priority to HK02104035.7Aprioritypatent/HK1042312A1/en
Assigned to NEKTAR THERAPEUTICS AL, CORPORATIONreassignmentNEKTAR THERAPEUTICS AL, CORPORATIONCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER CORPORATION
Priority to US10/647,621prioritypatent/US6894025B2/en
Priority to US11/112,118prioritypatent/US7214366B2/en
Assigned to NEKTAR THERAPEUTICSreassignmentNEKTAR THERAPEUTICSMERGER (SEE DOCUMENT FOR DETAILS).Assignors: NEKTAR THERAPEUTICS AL, CORPORATION
Assigned to WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENTreassignmentWELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENTGRANT OF SECURITY INTERESTAssignors: NEKTAR THERAPEUTICS
Anticipated expirationlegal-statusCritical
Assigned to NEKTAR THERAPEUTICSreassignmentNEKTAR THERAPEUTICSRELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141Assignors: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

A poly(ethylene glycol) derivative is disclosed that is activated with a sulfone moiety for selective attachment to thiol moieties on molecules and surfaces. The activated PEG is water soluble, hydrolytically stable for extended periods, and forms hydrolytically stable linkages with thiol moieties. The linkages generally are not reversible in reducing environments. The PEG derivative is useful for modifying the characteristics of substances including modifying biologically active molecules and surfaces for biocompatibility. Methods for synthesizing the active PEG and for preparing conjugates of the active PEG and other substances, including biologically active substances, are also disclosed.

Description

FIELD OF THE INVENTION
This invention relates to active derivatives of poly(ethylene glycol) and related hydrophilic polymers and to methods for their synthesis for use in modifying the characteristics of surfaces and molecules.
BACKGROUND OF THE INVENTION
Poly(ethylene glycol) ("PEG") has been studied for use in pharmaceuticals, on artificial implants, and in other applications where biocompatibility is of importance. Various derivatives of poly(ethylene glycol) ("PEG derivatives") have been proposed that have an active moiety for permitting PEG to be attached to pharmaceuticals and implants and to molecules and surfaces generally to modify the physical or chemical characteristics of the molecule or surface.
For example, PEG derivatives have been proposed for coupling PEG to surfaces to control wetting, static buildup, and attachment of other types of molecules to the surface, including proteins or protein residues. More specifically, PEG derivatives have been proposed for attachment to the surfaces of plastic contact lenses to reduce the buildup of proteins and clouding of vision. PEG derivatives have been proposed for attachment to artificial blood vessels to reduce protein buildup and the danger of blockage. PEG derivatives have been proposed for immobilizing proteins on a surface, as in enzymatic catalysis of chemical reactions.
In still further examples, PEG derivatives have been proposed for attachment to molecules, including proteins, for protecting the molecule from chemical attack, to limit adverse side effects of the molecule, or to increase the size of the molecule, thereby potentially to render useful substances that have some medicinal benefit, but are otherwise not useful or are even harmful to a living organism. Small molecules that normally would be excreted through the kidneys are maintained in the blood stream if their size is increased by attaching a biocompatible PEG derivative. Proteins and other substances that create an immune response when injected can be hidden to some degree from the immune system by coupling of a PEG molecule to the protein.
PEG derivatives have also been proposed for affinity partitioning of, for example, enzymes from a cellular mass. In affinity partitioning, the PEG derivative includes a functional group for reversible coupling to an enzyme that is contained within a cellular mass. The PEG and enzyme conjugate is separated from the cellular mass and then the enzyme is separated from the PEG derivative, if desired.
Coupling of PEG derivatives to proteins illustrates some of the problems that have been encountered in attaching PEG to surfaces and molecules. For many surfaces and molecules, the number of sites available for coupling reactions with a PEG derivative is somewhat limited. For example, proteins typically have a limited number and distinct type of reactive sites available for coupling. Even more problematic, some of the reactive sites may be responsible for the protein's biological activity, as when an enzyme catalyzes certain chemical reactions. A PEG derivative that attached to a sufficient number of such sites could adversely affect the activity of the protein.
Reactive sites that form the loci for attachment of PEG derivatives to proteins are dictated by the protein's structure. Proteins, including enzymes, are built of various sequences of alpha-amino acids, which have the general structure H2 N--CHR--COOH. The alpha amino moiety (H2 N--) of one amino acid joins to the carboxyl moiety (--COOH) of an adjacent amino acid to form amide linkages, which can be represented as --(NH--CHR--CO)n --, wheren can be hundreds or thousands. The fragment represented by R can contain reactive sites for protein biological activity and for attachment of PEG derivatives.
For example, in lysine, which is an amino acid forming part of the backbone of most proteins, an --NH2 moiety is present in the epsilon position as well as in the alpha position. The epsilon --NH2 is free for reaction under conditions of basic pH. Much of the art has been directed to developing PEG derivatives for attachment to the epsilon --NH2 moiety of the lysine fraction of a protein. These PEG derivatives all have in common that the lysine amino acid fraction of the protein typically is inactivated, which can be a drawback where lysine is important to protein activity.
Zalipsky U.S. Pat. No. 5,122,614 discloses that PEG molecules activated with an oxycarbonyl-N-dicarboximide functional group can be attached under aqueous, basic conditions by a urethane linkage to the amine group of a polypeptide. Activated PEG-N-succinimide carbonate is said to form stable, hydrolysis-resistant urethane linkages with amine groups. The amine group is shown to be more reactive at basic pHs of from about 8.0 to 9.5, and reactivity falls off sharply at lower pH. However, hydrolysis of the uncoupled PEG derivative also increases sharply at pH's of 8.0 to 9.5. Zalipsky avoids the problem of an increase in the rate of reaction of the uncoupled PEG derivative with water by using an excess of PEG derivative to bind to the protein surface. By using an excess, sufficient reactive epsilon amino sites are bound with PEG to modify the protein before the PEG derivative has an opportunity to become hydrolyzed and unreactive.
Zalipsky's method is adequate for attachment of the lysine fraction of a protein to a PEG derivative at one active site on the PEG derivative. However, if the rate of hydrolysis of the PEG derivative is substantial, then it can be problematic to provide attachment at more than one active site on the PEG molecule, since a simple excess does not slow the rate of hydrolysis.
For example, a linear PEG with active sites at each end will attach to a protein at one end, but, if the rate of hydrolysis is significant, will react with water at the other end to become capped with a relatively nonreactive hydroxyl moiety, represented structurally as --OH, rather than forming a "dumbbell" molecular structure with attached proteins or other desirable groups on each end. A similar problem arises if it is desired to couple a molecule to a surface by a PEG linking agent because the PEG is first attached to the surface or couples to the molecule, and the opposite end of the PEG derivative must remain active for a subsequent reaction. If hydrolysis is a problem, then the opposite end typically becomes inactivated.
Also disclosed in Zalipsky U.S. Pat. No. 5,122,614 are several other PEG derivatives from prior patents. PEG-succinoyl-N-hydroxysuccinimide ester is said to form ester linkages that have limited stability in aqueous media, thus indicating an undesirable short half-life for this derivative. PEG-cyanuric chloride is said to exhibit an undesirable toxicity and to be non-specific for reaction with particular functional groups on a protein. The PEG-cyanuric chloride derivative may therefore have undesirable side effects and may reduce protein activity because it attaches to a number of different types of amino acids at various reactive sites. PEG-phenylcarbonate is said to produce toxic hydrophobic phenol residues that have affinity for proteins. PEG activated with carbonyldiimidazole is said to be too slow in reacting with protein functional groups, requiring long reaction times to obtain sufficient modification of the protein.
Still other PEG derivatives have been proposed for attachment to functional groups on amino acids other than the epsilon --NH2 of lysine. Histidine contains a reactive imino moiety, represented structurally as --N(H)--, but many derivatives that react with epsilon --NH2 also react with --N(H)--. Cysteine contains a reactive thiol moiety, represented structurally as --SH, but the PEG derivative maleimide that is reactive with this moiety is subject to hydrolysis.
As can be seen from the small sampling above, considerable effort has gone into developing various PEG derivatives for attachment to, in particular, the --NH2 moiety on the lysine amino acid fraction of various proteins. Many of these derivatives have proven problematic in their synthesis and use. Some form unstable linkages with the protein that are subject to hydrolysis and therefore do not last very long in aqueous environments, such as in the blood stream. Some form more stable linkages, but are subject to hydrolysis before the linkage is formed, which means that the reactive group on the PEG derivative may be inactivated before the protein can be attached. Some are somewhat toxic and are therefore less suitable for use in vivo. Some are too slow to react to be practically useful. Some result in a loss of protein activity by attaching to sites responsible for the protein's activity. Some are not specific in the sites to which they will attach, which can also result in a loss of desirable activity and in a lack of reproducibility of results.
SUMMARY OF THE INVENTION
The invention provides water soluble and hydrolytically stable derivatives of poly(ethylene glycol) ("PEG") polymers and related hydrophilic polymers having one or more active sulfone moieties. These polymer derivatives with active sulfone moieties are highly selective for coupling with thiol moieties instead of amino moieties on molecules and on surfaces, especially at pHs of about 9 or less. The sulfone moiety, the linkage between the polymer and the sulfone moiety, and the linkage between the thiol moiety and the sulfone moiety are not generally reversible in reducing environments and are stable against hydrolysis for extended periods in aqueous environments at pHs of about 11 or less. Consequently, the physical and chemical characteristics of a wide variety of substances can be modified under demanding aqueous conditions with the active sulfone polymer derivatives.
For example, conditions for modification of biologically active substances can be optimized to preserve a high degree of biological activity. Pharmaceuticals from aspirin to penicillin can be usefully modified by attachment of active sulfone polymer derivatives if these pharmaceuticals are modified to contain thiol moieties. Large proteins containing cysteine units, which have active thiol moieties, can also be usefully modified. Techniques of recombinant DNA technology ("genetic engineering") can be used to introduce cysteine groups into desired places in a protein. These cysteines can be coupled to active sulfone polymer derivatives to provide hydrolytically stable linkages on a variety of proteins that do not normally contain cysteine units.
Specific sulfone moieties for the activated polymers of the invention are those having at least two carbon atoms joined to the sulfone group --SO2 -- with a reactive site for thiol specific coupling reactions on the second carbon from the sulfone group.
More specifically, the active sulfone moieties comprise vinyl sulfone, the active ethyl sulfones, including the haloethyl sulfones, and the thiol-specific active derivatives of these sulfones. The vinyl sulfone moiety can be represented structurally as --SO2 --CH═CH2 ; the active ethyl sulfone moiety can be represented structurally as --SO2 --CH2 --CH2 --Z, where Z can be halogen or some other leaving group capable of substitution by thiol to form the sulfone and thiol linkage --SO2 --CH2 --CH2 --S--W, where W represents a biologically active molecule, a surface, or some other substance. The derivatives of the vinyl and ethyl sulfones can include other substituents, so long as the water solubility and the thiol-specific reactivity of the reactive site on the second carbon are maintained.
The invention includes hydrolytically stable conjugates of substances having thiol moieties with polymer derivatives having active sulfone moieties. For example, a water soluble sulfone-activated PEG polymer can be coupled to a biologically active molecule at a reactive thiol site. The linkage by which the PEG and the biologically active molecule are coupled includes a sulfone moiety coupled to a thiol moiety and has the structure PEG--SO2 --CH2 CH2 --S--W, where W represents the biologically active molecule, whether the sulfone moiety prior to coupling of the PEG was vinyl sulfone or an active ethyl sulfone.
The invention also includes biomaterials comprising a surface having one or more reactive thiol sites and one or more of the water soluble sulfone-activated polymers of the invention coupled to the surface by a sulfone and thiol linkage. Biomaterials and other substances can also be coupled to the sulfone activated polymer derivatives through a linkage other than the sulfone and thiol linkage, such as a conventional amino linkage, to leave a more hydrolytically stable activating group, the sulfone moiety, available for subsequent reactions.
The invention includes a method of synthesizing the activated polymers of the invention. A sulfur containing moiety is bonded directly to a carbon atom of the polymer and then converted to the active sulfone moiety. Alternatively, the sulfone moiety can be prepared by attaching a linking agent that has the sulfone moiety at one terminus to a conventional activated polymer so that the resulting polymer has the sulfone moiety at its terminus.
More specifically, a water soluble polymer having at least one active hydroxyl moiety undergoes a reaction to produce a substituted polymer having a more reactive moiety thereon. The resulting substituted polymer undergoes a reaction to substitute for the more reactive moiety a sulfur-containing moiety having at least two carbon atoms where the sulfur in the sulfur-containing moiety is bonded directly to a carbon atom of the polymer. The sulfur-containing moiety then undergoes reactions to oxidize sulfur, --S--, to sulfone, --SO2 --, and to provide a sufficiently reactive site on the second carbon atom of the sulfone containing moiety for formation of linkages with thiol containing moieties.
Still more specifically, the method of synthesizing the activated polymers of the invention comprises reacting poly(ethylene glycol) with a hydroxyl activating compound to form an ester or with a halogen containing derivative to form a halogen substituted PEG. The resulting activated PEG is then reacted with mercaptoethanol to substitute the mercaptoethanol radical for the ester moiety or the halide. The sulfur in the mercaptoethanol moiety is oxidized to sulfone. The ethanol sulfone is activated by either activating the hydroxyl moiety or substituting the hydroxyl moiety with a more active moiety such as halogen. The active ethyl sulfone of PEG can then be converted to vinyl sulfone, if desired, by cleaving the activated hydroxyl or other active moiety and introducing the carbon-carbon double bond adjacent the sulfone group --SO2 --.
The invention also includes a method for preparing a conjugate of a substance with a polymer derivative that has an active sulfone moiety. The method includes the step of forming a linkage between the polymer derivative and the substance, which linkage can be between the sulfone moiety and a thiol moiety.
Thus the invention provides activated polymers that are specific in reactivity, stable in water, stable in reducing environments, and that form more stable linkages with surfaces and molecules, including biologically active molecules, than previously has been achieved. The activated polymer can be used to modify the characteristics of surfaces and molecules where biocompatibility is of importance. Because the activated polymer is stable under aqueous conditions and forms stable linkages with thiol moieties, the most favorable reaction conditions can be selected for preserving activity of biologically active substances and for optimizing the rate of reaction for polymer coupling.
DETAILED DESCRIPTION OF THE INVENTION
The synthetic route used to prepare active sulfones of poly(ethylene glycol) and related polymers comprises at least four steps in which sulfuris bound to a polymer molecule and then converted through a series of reactions to an active sulfone functional group. The starting PEG polymer molecule has at least one hydroxyl moiety, --OH, that is available to participate in chemical reactions and is considered to be an "active" hydroxyl moiety. The PEG molecule can have multiple active hydroxyl moieties available for chemical reaction, as is explained below. These active hydroxyl moieties are in fact relatively nonreactive, and the firststep in the synthesis is to prepare a PEG having a more reactive moiety.
A more reactive moiety typically will be created by one of two routes, hydroxyl activation or substitution. Other methods are available as shouldbe apparent to the skilled artisan, but hydroxyl activation and substitution are the two most often used. In hydroxyl activation, the hydrogen atom --H on the hydroxyl moiety --OH is replaced with a more active group. Typically, an acid or an acid derivative such as an acid halide is reacted with the PEG to form a reactive ester in which the PEG and the acid moiety are linked through the ester linkage. The acid moiety generally is more reactive than the hydroxyl moiety. Typical esters are the sulfonate, carboxylate, and phosphate esters.
Sulfonyl acid halides that are suitable for use in practicing the inventioninclude methanesulfonyl chloride and p-toluenesulfonyl chloride. Methanesulfonyl chloride is represented structurally as CH3 SO2 Cl and is also known as mesyl chloride. Methanesulfonyl esters are sometimes referred to as mesylates. Para-toluenesulfonyl chloride is represented structurally as H3 CC6 H4 SO2 Cl and is also known as tosyl chloride. Toluenesulfonyl esters are sometimes referred to as tosylates.
In a substitution reaction, the entire --OH group on the PEG is substitutedby a more reactive moiety, typically a halide. For example, thionyl chloride, represented structurally as SOCl2, can be reacted with PEG to form a more reactive chlorine substituted PEG. Substitution of the hydroxyl moiety by another moiety is sometimes referred to in the art as hydroxyl activation. The term "hydroxyl activation" should be interpreted herein to mean substitution as well as esterification and other methods ofhydroxyl activation.
The terms "group," "functional group," "moiety," "active moiety," "reactivesite," and "radical" are somewhat synonymous in the chemical arts and are used in the art and herein to refer to distinct, definable portions or units of a molecule and to units that perform some function or activity and are reactive with other molecules or portions of molecules. In this sense a protein or a protein residue can be considered a molecule or as a functional group or moiety when coupled to a polymer.
The term "PEG" is used in the art and herein to describe any of several condensation polymers of ethylene glycol having the general formula represented by the structure H(OCH2 CH2)n OH which can alsobe represented as HO--CH2 CH2 --(OCH2 CH2)n --OH. PEG is also known as polyoxyethylene, polyethylene oxide, polyglycol, and polyether glycol. PEG can be prepared as copolymers of ethylene oxide and many other monomers.
Poly(ethylene glycol) is used in biological applications because it has properties that are highly desirable and is generally approved for biological or biotechnical applications. PEG typically is clear, colorless, odorless, soluble in water, stable to heat, inert to many chemical agents, does not hydrolyze or deteriorate, and is nontoxic. Poly(ethylene glycol) is considered to be biocompatible, which is to say that PEG is capable of coexistence with living tissues or organisms without causing harm. More specifically, PEG is not immunogenic, which is to say that PEG does not tend to produce an immune response in the body. When attached to a moiety having some desirable function in the body, the PEG tends to mask the moiety and can reduce or eliminate any immune response so that an organism can tolerate the presence of the moiety. Accordingly, the sulfone-activated PEGs of the invention should be substantially non-toxic and should not tend substantially to produce an immune response or cause clotting or other undesirable effects.
The second step in the synthesis is to link sulfur directly to a carbon atom in the polymer and in a form that can be converted to an ethyl sulfone or ethyl sulfone derivative having similar reactive properties. "Ethyl" refers to a moiety having an identifiable group of two carbon atoms joined together. The active sulfone PEG derivative requires that thesecond carbon atom in the chain away from the sulfone group provide a reactive site for linkages of thiol moieties with the sulfone. This resultcan be achieved by reacting the active moiety produced in the first step mentioned above, which typically will be the ester or halide substituted PEG, in a substitution reaction with an alcohol that also contains a reactive thiol moiety attached to an ethyl group, a thioethanol moiety. The thiol moiety is oxidized to sulfone and the second carbon away from the sulfone on the ethyl group is converted to a reactive site.
Compounds containing thiol moieties, --SH, are organic compounds that resemble alcohols, which contain the hydroxyl moiety --OH, except that in thiols, the oxygen of at least one hydroxyl moiety is replaced by sulfur. The activating moiety on the PEG derivative from the first reaction, whichtypically is either halide or the acid moiety of an ester, is cleaved from the polymer and is replaced by the alcohol radical of the thioethanol compound. The sulfur in the thiol moiety of the alcohol is linked directlyto a carbon on the polymer.
The alcohol should be one that provides a thioethanol moiety for attachmentdirectly to the carbon of the polymer chain, or that can easily be converted to a thioethanol moiety or substituted moiety of similar reactive properties. An example of such an alcohol is mercaptoethanol, which is represented structurally as HSCH2 CH2 OH and is sometimes also called thioethanol.
In the third step of the synthesis, an oxidizing agent is used to convert the sulfur that is attached to the carbon to the sulfone group, --SO2. There are many such oxidizing agents, including hydrogen peroxide and sodium perborate. A catalyst, such as tungstic acid, can be useful. However, the sulfone that is formed is not in a form active for thiol-selective reactions and it is necessary to remove the relatively unreactive hydroxyl moiety of the alcohol that was added in the substitution reaction of the second step.
In the fourth step, the hydroxyl moiety of the alcohol that was added in the second step is converted to a more reactive form, either through activation of the hydroxyl group or through substitution of the hydroxyl group with a more reactive group, similar to the first step in the reaction sequence. Substitution typically is with halide to form a haloethyl sulfone or a derivative thereof having a reactive site on the second carbon removed from the sulfone moiety. Typically, the second carbon on the ethyl group will be activated by a chloride or bromide halogen. Hydroxyl activation should provide a site of similar reactivity, such as the sulfonate ester. Suitable reactants are the acids, acid halides, and others previously mentioned in connection with the first stepin the reaction, especially thionyl chloride for substitution of the hydroxyl group with the chlorine atom.
The resulting polymeric activated ethyl sulfone is stable, isolatable, and suitable for thiol-selective coupling reactions. As shown in the examples,PEG chloroethyl sulfone is stable in water at a pH of about 7 or less, but nevertheless can be used to advantage for thiol-selective coupling reactions at conditions of basic pH up to at least about pH 9.
In the thiol coupling reaction, it is possible that the thiol moiety displaces chloride, as in the following reaction:
PEG-SO.sub.2 --CH.sub.2 --CH.sub.2 --Cl+W--S--H→PEG--SO.sub.2 --CH.sub.2 --CH.sub.2 --S--W,
where W represents the moiety to which the thiol moiety SH is linked and can be a biologically active molecule, a surface, or some other substance.However, and while not wishing to be bound by theory, it is believed, basedon the observable reaction kinetics as shown in Example 3, that the chloroethyl and other activated ethyl sulfones and reactive derivatives are converted to PEG vinyl sulfone, and that it is the PEG vinyl sulfone or derivative thereof that is actually linked to the thiol moiety. Nevertheless, the resulting sulfone and thiol linkage is not distinguishable, whether from active PEG ethyl sulfone or from PEG vinyl sulfone, and so the active ethyl sulfone can be used at pHs above 7 for linking to thiol groups.
PEG vinyl sulfone is also stable and isolatable and can form thiol-selective, hydrolytically stable linkages, typically in much less time than the haloethyl sulfone or other activated ethyl sulfone, as explained further below.
In a fifth step that can be added to the synthesis, the activated ethyl sulfone is reacted with any of a variety of bases, such as sodium hydroxide or triethylamine, to form PEG vinyl sulfone or one of its activederivatives for use in thiol-selective coupling reactions.
As shown in the examples below, especially Example 3, PEG vinyl sulfone reacts quickly with thiol moieties and is stable against hydrolysis in water of pH less than about 11 for at least several days. The reaction canbe represented as follows:
PEG--SO.sub.2 --CH═CH.sub.2 +W--S--H→PEG--SO.sub.2 --CH.sub.2 --CH.sub.2 --S--W.
The thiol moiety is said to add "across the double bond." The W-S moiety adds to the terminal CH2 of the double bond, which is the second carbon from the sulfone group SO2. The hydrogen H adds to the CH of the double bond. However, at a pH of above about 9, selectivity of the sulfone moiety for thiol is diminished and the sulfone moiety becomes somewhat more reactive with amino groups.
Alternatively to the above synthesis, the sulfone-activated PEG derivativescan be prepared by attaching a linking agent having a sulfone moiety to a PEG activated with a different functional group. For example, an amino activated PEG, PEG-NH2, is reacted under favorable conditions of pH of about 9 or less with a small molecule that has a succinimidyl active ester moiety NHS--O2 C-- at one terminus and a sulfone moiety, vinyl sulfone --SO2 --CH═CH2, at the other terminus. The amino activated PEG forms a stable linkage with the succinimidyl ester. The resulting PEG is activated with the vinyl sulfone moiety at the terminus and is hydrolytically stable. The reaction and the resulting vinyl sulfoneactivated PEG are represented structurally as follows:
PEG-NH.sub.2 +NHS--O.sub.2 C--CH.sub.2 --CH.sub.2 --SO.sub.2 CH═CH.sub.2 →PEG-NH--OC--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2.
A similar activated PEG could be achieved by reacting an amine-activated PEG such as succinimidyl active ester PEG, PEG-CO2 --NHS, with a small molecule that has an amine moiety at one terminus and a vinyl sulfone moiety at the other terminus. The succinimidyl ester forms a stable linkage with the amine moiety as follows:
PEG-CO.sub.2 --NHS+NH.sub.2 --CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2 →PEG-CO--NH--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2.
The active PEG sulfones of the invention can be of any molecular weight andcan be linear or branched with hundreds of arms. The PEG can be substitutedor unsubstituted so long as at least one reactive site is available for substitution with the sulfone moieties. PEG typically has average molecular weights of from 200 to 100,000 and its biological properties canvary with molecular weight and depending on the degree of branching and substitution, so not all of these derivatives may be useful for biologicalor biotechnical applications. For most biological and biotechnical applications, substantially linear, straight-chain PEG vinyl sulfone or bis vinyl sulfone or activated ethyl sulfone will be used, substantially unsubstituted except for the vinyl sulfone or ethyl sulfone moieties and, where desired, other additional functional groups. For many biological andbiotechnical applications, the substituents would typically be unreactive groups such as hydrogen H- and methyl CH3 -- ("m-PEG").
The PEG can have more than one vinyl sulfone or precursor moiety attached or the PEG can be capped on one end with a relatively nonreactive moiety such as the methyl radical, --CH3. The capped form can be useful, forexample, if it is desirable simply to attach the polymer chains at various thiol sites along a protein chain. Attachment of PEG molecules to a biologically active molecule such as a protein or other pharmaceutical or to a surface is sometimes referred to as "PEGylation."
A linear PEG with active hydroxyls at each end can be activated at each endwith vinyl sulfone or its precursor or derivatives of similar reactivity tobecome bifunctional. The bifunctional structure, PEG bis vinyl sulfone, forexample, is sometimes referred to as a dumbbell structure and can be used, for example, as a linker or spacer to attach a biologically active molecule to a surface or to attach more than one such biologically active molecule to the PEG molecule. The stability of the sulfone moiety against hydrolysis makes it particularly useful for bifunctional or heterobifunctional applications.
Another application for PEG vinyl sulfone and its precursor is dendritic activated PEG in which multiple arms of PEG are attached to a central corestructure. Dendritic PEG structures can be highly branched and are commonlyknown as "star" molecules. Star molecules are generally described in Merrill U.S. Pat. No. 5,171,264, the contents of which are incorporated herein by reference. The sulfone moieties can be used to provide an active, functional group on the end of the PEG chain extending from the core and as a linker for joining a functional group to the star molecule arms.
PEG vinyl sulfone and its precursors and derivatives can be used for attachment directly to surfaces and molecules having a thiol moiety. However, more typically a heterobifunctional PEG derivative having a sulfone moiety on one terminus and a different functional moiety on the opposite terminus group will be attached by the different moiety to a surface or molecule. When substituted with one of the other active moieties, the heterobifunctional PEG dumbbell structure can be used, for example, to carry a protein or other biologically active molecule by sulfone linkages on one end and by another linkage on the other end, such as an amine linkage, to produce a molecule having two different activities. A heterobifunctional PEG having a sulfone moiety on one end and an amine specific moiety on the other end could be attached to both cysteine and lysine fractions of proteins. A stable amine linkage can be achieved and then the hydrolytically stable unreacted sulfone moiety is available for subsequent thiol-specific reactions as desired.
Other active groups for heterobifunctional sulfone-activated PEGs can be selected from among a wide variety of compounds. For biological and biotechnical applications, the substituents would typically be selected from reactive moieties typically used in PEG chemistry to activate PEG such as the aldehydes, trifluoroethylsulfonate, which is also sometimes called tresylate, n-hydroxylsuccinimide ester, cyanuric chloride, cyanuricfluoride, acyl azide, succinate, the p-diazo benzyl group, the 3-(p-diazophenyloxy)-2-hydroxy propyloxy group, and others.
Examples of active moieties other than sulfone are shown in Davis et al. U.S. Pat. No. 4,179,337; Lee et al. U.S. Pat. Nos. 4,296,097 and 4,430,260; Iwasaki et al. 4,670,417; Katre et al. U.S. Pat. Nos. 4,766,106; 4,917,888; and 4,931,544; Nakagawa et al. U.S. Pat. No. 4,791,192; Nitecki et al. U.S. Pat. No. 4,902,502 and 5,089,261; Saifer U.S. Pat. No. 5,080,891; Zalipsky U.S. Pat. No. 5,122,614; Shadle et al. U.S. Pat. No. 5,153,265; Rhee et al. U.S. Pat. No. 5,162,430; European Patent Application Publication No. 0 247 860; and PCT International Application Nos. US86/01252; GB89/01261; GB89/01262; GB89/01263; US90/03252; US90/06843; US91/06103; US92/00432; and US92/02047, the contents of which are incorporated herein by reference.
It should be apparent to the skilled artisan that the dumbbell structures discussed above could be used to carry a wide variety of substituents and combinations of substituents. Pharmaceuticals such as aspirin, vitamins, penicillin, and others too numerous to mention; polypeptides or proteins and protein fragments of various functionalities and molecular weights; cells of various types; surfaces for biomaterials, almost any substance could be modified. As used herein, the term "protein" should be understoodto include peptides and polypeptides, which are polymers of amino acids. The term "biomaterial" means a material, typically synthetic and sometimesmade of plastic, that is suitable for implanting in a living body to repairdamaged or diseased parts. An example of a biomaterial is artificial blood vessels.
One straight chain PEG derivative of the invention for biological and biotechnical applications has the basic structure R--CH2 CH2 --(OCH2 CH2)n --Y. The PEG monomer OCH2 CH2 preferably is substantially unsubstituted and unbranched along the polymerbackbone. The subscript "n " can equal from about 5 to 3,000 A more typical range is from about 5 to 2,200, which corresponds to a molecular weight of from about 220 to 100,000. Still more typical is a range of fromabout 34 to 1,100, which corresponds to a molecular weight range of from about 1,500 to 50,000. Most applications will be accomplished with molecular weights in the neighborhood of 2,000 to 5,000, which correspondsto a value ofn of from about 45 to 110.
In the above structure, Y represents --SO2 CH═CH2 or --SO2 --CH2 --CH2 X where X is a halogen. R represents a group that may be the same or different from Y. R can be H--, HO--, H3 CO, CH2 ═CH--SO2 --, Cl--CH2 --CH2 --SO2 --, or a polymer activating group other than CH2 ═CH--SO2 --, Cl--CH2 --CH2 --SO2 --, such as is referred to with respect to the above patents and published patent applications.
The active polymer derivatives are water soluble and hydrolytically stable and produce water soluble and hydrolytically stable linkages with thiol groups. The derivatives are considered infinitely soluble in water or as approaching infinite solubility and can enable otherwise insoluble molecules to pass into solution when conjugated with the derivative.
Hydrolytic stability of the derivatives means that the linkage between the polymer and the sulfone moiety is stable in water and that the vinyl sulfone moiety does not react with water at a pH of less than about 11 foran extended period of time of at least several days, and potentially indefinitely, as shown in Example 3 below. The activated ethyl sulfone canbe converted to the vinyl sulfone at conditions of basic pH, with the same resulting stability. Hydrolytic stability of the thiol linkage means that conjugates of the activated polymer and a substance having a thiol moiety are stable at the sulfone-thiol linkage for an extended period of time in aqueous environments at a pH of below about 11. Most proteins could be expected to lose their activity at a caustic pH of 11 or higher, so it should be apparent to the skilled artisan that many applications for the active sulfone PEG derivatives will be at pHs of less than 11, regardless of the stability of the sulfone moiety at higher pH.
To be useful for modification of proteins and other substances, it is only necessary that the sulfone be stable for a period of time sufficient to permit the sulfone to react with a reactive thiol moiety on the protein orother substance. The rate of reaction of the sulfone moiety with thiol can vary with pH, as shown in Example 2 below, from about 2 minutes to 30 minutes, which is much faster than the rate of hydrolysis, if any. Vinyl sulfone could be expected to react with thiol over a much broader range ofreaction times since it is stable for long periods of time. Also, as shown in Example 3 below, at conditions of basic pH chloroethyl sulfone is not hydrolyzed, but is converted to vinyl sulfone, which remains stable for several days and is even more reactive toward thiol groups. Accordingly, for the purpose of modifying the characteristics of substances, the activeethyl sulfones can also be considered to be hydrolytically stable for an extended period of time over a broad pH range.
Other water soluble polymers than PEG are believed to be suitable for similar modification and activation with an active sulfone moiety. These other polymers include poly(vinyl alcohol) ("PVA"); other poly(alkylene oxides) such as poly(propylene glycol) ("PPG") and the like; and poly(oxyethylated polyols) such as poly(oxyethylated glycerol), poly(oxyethylated sorbitol), and poly(oxyethylated glucose), and the like.The polymers can be homopolymers or random or block copolymers and terpolymers based on the monomers of the above polymers, straight chain orbranched, or substituted or unsubstituted similar to PEG, but having at least one active site available for reaction to form the sulfone moiety.
The following Example 1 shows the synthesis, isolation, and characterization of poly(ethylene glycol) chloroethyl sulfone followed by the preparation of poly(ethylene glycol) vinyl sulfone from the chloroethyl sulfone. Preparation of other polymeric sulfones having a reactive site on the second carbon from the sulfone group is similar and the steps for doing so should be apparent to the skilled artisan based on Example 1 below and the polymers listed above.
Example 1: Synthesis
The reaction steps can be illustrated structurally as follows:
(1) PEG-OH+CH3 SO2 Cl→PEG-OSO2 CH3
(2) PEG-OSO2 CH3 +HSCH2 CH2 OH→PEG-SCH2 CH2 OH
(3) PEG-SCH2 CH2 OH+H2 O2 →PEG-SO2 CH2CH2 OH
(4) PEG-SO2 CH2 CH2 OH+SOCl2 →PEG-SO2 CH2 CH2 Cl
(5) PEG-SO2 --CH2 CH2 Cl+NaOH→PEG-SO2 --CH═CH2 +HCl
Each of the above reactions is described in detail below:
Reaction 1. Reaction 1 represents the preparation of the methane sulfonyl ester of poly(ethylene glycol), which can also be referred to as the methanesulfonate or mesylate of poly(ethylene glycol). The tosylate and the halides can be prepared by similar procedures, which are believed to be apparent to the skilled artisan.
To prepare the mesylate, twenty-five grams of PEG of molecular weight 3400 was dried by azeotropic distillation in 150 ml of toluene. Approximately half of the toluene was distilled off in drying the PEG. Forty ml of dry dichloromethane was added to the toluene and PEG solution, followed by cooling in an ice bath. To the cooled solution was added 1,230 ml of distilled methanesulfonyl chloride, which is an equivalent weight of 1.06 with respect to PEG hydroxyl groups, and 2,664 ml of dry triethylamine, which is an equivalent weight of 1.3 with respect to PEG hydroxyl groups. "Equivalent weight" as used above can be thought of as "combining weight" and refers to the weight of a compound that will react with an equivalent weight of PEG hydroxyl groups.
The reaction was permitted to sit overnight during which time it warmed to room temperature. Triethylammonium hydrochloride precipitated and the precipitate was removed by filtration. Thereafter, the volume was reduced by rotary evaporation to 20 ml. The mesylate was precipitated by addition to 100 ml of cold dry ethyl ether. Nuclear magnetic resonance (NMR) analysis showed 100% conversion of hydroxyl groups to mesylate groups.
Reaction 2. Reaction 2 represents the formation of poly(ethylene glycol) mercaptoethanol by reaction of the mesylate with mercaptoethanol. The reaction causes the methanesulfonate radical to be displaced from the PEG.The sulfur in the mercaptoethanol radical is attached directly to the carbon in the carbon-carbon backbone of the PEG.
Twenty grams of the mesylate from reaction 1 was dissolved in 150 ml of distilled water. The solution of mesylate and water was cooled by immersion in an ice bath. To the cooled solution was added 2,366 ml of mercaptoethanol, which is 3 equivalent weights with respect to PEG hydroxyl groups. Also added was 16.86 ml of 2N NaOH base. The reaction wasrefluxed for 3 hours, which means that the vapors rising from the reaction were continuously condensed and allowed to flow back into the reaction.
The poly(ethylene glycol) mercaptoethanol product was extracted three timeswith dichloromethane using approximately 25 ml of dichloromethane each time. The organic fractions were collected and dried over anhydrous magnesium sulfate. The volume was reduced to 20 ml and the product was precipitated by addition to 150 ml of cold dry ether.
NMR analysis in d6 -DMSO dimethyl sulfoxide gave the following peaks for PEG-SCH2 CH2 OH: 2.57 ppm, triplet, --CH2 --S--; 2.65 ppm, triplet, --S--CH2 --; 3.5 ppm, backbone singlet; and 4.76 ppm, triplet, --OH. The hydroxyl peak at 4.76 ppm indicated 81% substitution. However, the 2.65 ppm peak for --S--CH2 -- indicated 100% substitution. It has been observed that hydroxyl peaks frequently give lowfigures on percent substitution, and so the 2.65 ppm peak for --S--CH2 -- is considered to be more reliable and to confirm 100% substitution.
Reaction 3. Reaction 3 represents peroxide oxidation of the poly(ethylene glycol) mercaptoethanol product to convert the sulfur, S, to sulfone, SO2. PEG ethanol sulfone is produced.
Twenty grams of PEG-SCH2 CH2 OH was dissolved in 30 ml of 0,123M tungstic acid solution and cooled in an ice bath. The tungstic acid solution was prepared by dissolving the acid in sodium hydroxide solution of pH 11.5 and then adjusting the pH to 5.6 with glacial acetic acid. Twenty ml of distilled water and 2.876 ml of 30% hydrogen peroxide, which has an equivalent weight of 2.5 with respect to hydroxyl groups, was addedto the solution of tungstic acid and poly(ethylene glycol) mercaptoethanol and the reaction was permitted to warm overnight to room temperature.
The oxidized product was extracted three times with dichloromethane using 25 ml of dichloromethane each time. The collected organic fractions were washed with dilute aqueous sodium bicarbonate and dried with anhydrous magnesium sulfate. The volume was reduced to 20 ml. The PEG ethanol sulfone product was precipitated by addition to cold dry ethyl ether.
NMR analysis in d6-DMSO dimethyl sulfoxide gave the following peaks for PEG-SO2 CH2 CH2 OH: 3.25 ppm, triplet, --CH2 --SO2 --; 3.37 ppm, triplet, --SO2 --CH2 --; 3.50 ppm, backbone; 3.77 ppm, triplet, --CH2 OH; 5.04 ppm, triplet, --OH. The hydroxyl peak at 5.04 ppm indicated 85% substitution. However, the peak at3.37 ppm for --SO2 --CH2 -- indicated 100% substitution and is considered to be more reliable.
Reaction 4. Reaction 4 represents the final step in synthesis, isolation, and characterization of poly(ethylene glycol) chloroethyl sulfone.
To synthesize the product, twenty grams of PEG-SO2 CH2 CH2 OH poly(ethylene glycol) ethanol sulfone was dissolved in 100 ml of freshly distilled thionyl chloride and the solution was refluxed overnight. The thionyl chloride had been distilled over quinoline. Excess thionyl chloride was removed by distillation. Fifty milliliters of tolueneand 50 ml of dichloromethane were added and removed by distillation.
To isolate the product, the PEG chloroethyl sulfone was dissolved in 20 ml of dichloromethane and precipitated by addition to 100 ml of cold dry ethyl ether. The precipitate was recrystallized from 50 ml of ethyl acetate to isolate the product.
Nuclear magnetic resonance was used to characterize the product. NMR analysis of PEG-SO2 CH2 CH2 Cl in d6 -DMSO dimethyl sulfoxide gave the following peaks: 3.50 ppm, backbone; 3.64 ppm, triplet, --CH2 SO2 --; 3.80 ppm, triplet, --SO2 --CH2 --. A small hydroxyl impurity triplet appeared at 3.94 ppm. Calculation of the percentage substitution was difficult for this spectrum because of the proximity of the important peaks to the very large backbone peak.
Reaction 5. Reaction 5 represents conversion of poly(ethylene glycol) chloroethyl sulfone from reaction step 4 to poly(ethylene glycol) vinyl sulfone and isolation and characterization of the vinyl sulfone product.
The PEG vinyl sulfone was readily prepared by dissolving solid PEG chloroethyl sulfone in dichloromethane solvent followed by addition of twoequivalents of NaOH base. The solution was filtered to remove the base and the solvent was evaporated to isolate the final product PEG-SO2 --CH═CH2 PEG vinyl sulfone.
The PEG vinyl sulfone was characterized by NMR analysis in d6 -DMSO dimethyl sulfoxide. NMR analysis showed the following peaks: 3.50 ppm, backbone; 3.73 ppm, triplet, --CH2 --SO2 --; 6.21 ppm, triplet, ═CH2 ; 6.97 ppm, doublet of doublets, --SO2 --CH--. The 6.97ppm peak for --SO2 --CH-- indicated 84% substitution. The 6.21 ppm peak for ═CH2 indicated 94% substitution. Titration with mercaptoethanol and 2,2'-dithiodipyridine indicated 95% substitution.
Example 2: Thiol-selective Reactivity
Example 2 shows that PEG vinyl sulfone and its precursor PEG chloroethyl sulfone are significantly more reactive with thiol groups (--SH) than withamino groups (--NH2) or imino groups (--NH--). Compounds containing thiol groups are organic compounds that resemble alcohols, which contain the hydroxyl group --OH, except that in thiols, the oxygen of the hydroxylgroup is replaced by sulfur. Thiols sometimes are also called sulfhydryls or mercaptans. PEG vinyl sulfone contains the vinyl sulfone group --SO2 --CH═CH.sub.2. PEG chloroethyl sulfone contains the chloroethyl sulfone group --SO2 CH2 CH2 Cl.
Selectivity for thiols is important in protein modification because it means that cysteine units (containing --SH) will be modified in preferenceto lysine units (containing --NH2) and histidine units (containing --NH--). The selectivity of PEG vinyl sulfone for thiols means that PEG can be selectively attached to cysteine units, thus preserving protein activity for specific proteins and controlling the number of PEG moleculesattached to the protein.
The relative reactivity of PEG vinyl sulfone with thiol and amino groups was determined by measuring the rates of reaction of PEG vinyl sulfone with N-α-acetyl lysine methyl ester and with mercaptoethanol. N-α-acetyl lysine methyl ester is a lysine model containing an aminogroup and is abbreviated Lys-NH2. Mercaptoethanol serves as a cysteinemodel containing a thiol group and is abbreviated Cys-SH. Relative reactivity of PEG chloroethyl sulfone was similarly determined. This molecule may serve as a "protected" form of the vinyl sulfone since it is stable in acid but converts to PEG vinyl sulfone upon addition of base.
Reactivity for PEG vinyl sulfone and for the PEG chloroethyl sulfone precursor was investigated at pH 8.0, pH 9.0, and at pH 9.5. Buffers for controlling the pH were 0.1 M phosphate at pH 8.0 and 0.1 M borate at pH 9.0 and at pH 9.5. For measurement of mercaptoethanol reactivity, 5 mM ethylenediamine tetraacetic acid (EDTA) was added to both buffers to retard conversion of thiol to disulfide.
For reaction of the PEG derivatives of the invention with Lys-NH2, a 3mM solution of the PEG derivative was added under stirring to a 0.3 mM Lys-NH2 solution in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by addition of fluorescamine to the reaction solution to produce a fluorescent derivativefrom reaction with remaining amino groups. The monitoring step was performed by adding 50 μL of reaction mixture to 1.950 mL of phosphate buffer of ph 8.0 followed by adding 1.0 mL of fluorescamine solution undervigorous stirring. The fluorescamine solution was 0.3 mg fluorescamine per ml of acetone.
Fluorescence was measured 10 minutes after mixing. Excitation was shown at wavelength 390 nm. Light emission occurred at 475 nm. No reaction was observed in 24 hours for either PEG vinyl sulfone or PEG chloroethyl sulfone at pH 8.0. At pH 9.5 the reaction was slow, but all amino groups were reacted after several days.
For reaction of the PEG vinyl sulfone and PEG chloroethyl sulfone precursorwith Cys-SH, a 2 mM solution of the PEG derivative was added to a 0.2 mM solution of Cys-SH in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by adding 4-dithiopyridine to the reaction solution. The 4-dithiopyridine compound reacts with Cys-SH to produce 4-thiopyridone, which absorbs ultraviolet light.
The monitoring step was performed by adding 50μL of reaction mixture to 0.950 mL of 0.1 M phosphate buffer at pH 8.0 and containing 5 mM EDTA, followed by adding one mL of 2 mM 4-dithiopyridine in the same buffer.
Absorbance of 4-thiopyridone was measured at 324 nm. Both PEG vinyl sulfoneand PEG chloroethyl sulfone showed reactivity toward Cys-SH, with PEG vinylsulfone showing greater reactivity. At pH 9.0 the reaction is over within two minutes using the vinyl sulfone and within 15 minutes using the chloroethyl sulfone. However, these reactions were too fast for determination of accurate rate constants. At pH 8.0 the reactions were slower, but still complete in one hour for vinyl sulfone and in three hours for the chloroethyl sulfone. The conversion of chloroethyl sulfone to vinyl sulfone is significantly slower than the reaction of vinyl sulfone with Cys-SH. Thus the rate of reaction for chloroethyl sulfone with Cys-SH appears to be dependent on the rate of conversion of chloroethyl sulfone to vinyl sulfone. Nevertheless, these reaction rates were still much faster than for the reaction with Lys-NH2.
The above kinetic studies demonstrate the following points. PEG vinyl sulfone is much more reactive with thiol groups than with amino groups, indicating that attachment of PEG vinyl sulfone to a protein containing both cysteine and lysine groups proceeds primarily by reaction with cysteine. Since reactivity with amino groups is similar to imino groups, then reactivity of histidine subunits will also be much lower than reactivity with cysteine subunits. Also, selectivity toward thiol groups is accentuated at lower pH values for PEG chloroethyl sulfone and PEG vinyl sulfone, although the reactions of PEG chloroethyl sulfone are somewhat slower.
The utility of many PEG derivatives is limited because they react rapidly with water, thus interfering with attempts to attach the derivative to molecules and surfaces under aqueous conditions. The following Example 3 shows that PEG vinyl sulfone and PEG chloroethyl sulfone are stable in water.
Example 3: Hydroytic Stability
PEG vinyl sulfone was dissolved in heavy water, D2 O deuterium oxide, and monitored by NMR. Reaction did not occur. A solution of PEG chloroethyl sulfone produced PEG vinyl sulfone in heavy water that was buffered with borate to pH 9.0. Monitoring with NMR showed that PEG vinyl sulfone, once produced, was stable for three days in heavy water.
PEG chloroethyl sulfone is stable in water until solution becomes basic, atwhich time it is converted into vinyl sulfone. Conversion to vinyl sulfone has been demonstrated by dissolving PEG chloroethyl sulfone in water at pH7 and in borate buffer at pH 9. The PEG derivative is extracted into methylene chloride. Removal of methylene chloride, followed by NMR analysis showed that PEG chloroethyl sulfone is stable at a neutral pH of 7.0, and reacts with base to produce PEG vinyl sulfone.
Vinyl sulfone is stable for several days in water, even at basic pH. Extensive hydrolytic stability and thiol-specific reactivity of PEG vinyl sulfone means that PEG vinyl sulfone and its precursor are useful for modification of molecules and surfaces under aqueous conditions, as shown in the following Example 4.
Example 4: Protein Conjugation
Protein modification was demonstrated by attachment of the PEG derivative to bovine serum albumin (BSA) by two different methods. BSA is a protein. Native unmodified BSA contains cystine groups which do not contain thiol groups. The cystine units are tied up as disulfide linkages, S--S.
In the first method, m-PEG vinyl sulfone of molecular weight 5,000 was reacted with unmodified BSA for 24 hours in a 0.1 M borate buffer at pH 9.5 at room temperature. The solution contained 1 mg of BSA and 1 mg of m-PEG vinyl sulfone of molecular weight 5,000 per ml of solution. The results from the Example 2 model compounds had indicated that lysine subunits (and possibly histidine subunits) would be modified under these relatively basic conditions and in the absence of free thiol groups available for reaction.
Attachment to lysine subunits was demonstrated in two ways. First, size exclusion chromatography showed that the molecular weight of the protein had increased by approximately 50%, thus indicating attachment of approximately 10 PEGs to the protein. Second, fluorescamine analysis showed that the number of lysine groups in the BSA molecule had been reduced by approximately ten.
In the second method, the BSA was treated with tributylphosphine to reduce the disulfide S--S bonds to thiol groups, --SH, which are available for reaction. The modified BSA was then treated with PEG chloroethyl sulfone at pH 8.0 in a 0.1 M phosphate buffer at room temperature for 1 hour. The solution contained 1 mg of modified BSA and 1 mg of m-PEG chloroethyl sulfone of molecular weight 5,000 per ml of solution. The results showed that lysine groups were unreactive under these conditions. However, thiol groups were reactive.
Attachment of the PEG to the protein was demonstrated by size exclusion chromatography, which showed an increase in the molecular weight of the protein by about 25%. Fluorescamine analysis indicated no change in numberof lysine subunits in the protein, thus confirming that PEG attachment did not take place on lysine subunits. Substitution on thiol groups was thereby confirmed.
The invention claimed herein has been described with respect to particular exemplified embodiments. However, the foregoing description is not intended to limit the invention to the exemplified embodiments, and the skilled artisan should recognize that variations can be made within the spirit and scope of the invention as described in the foregoing specification. On the contrary, the invention includes all alternatives, modifications, and equivalents that may be included within the true spiritand scope of the invention as defined by the appended claims.

Claims (25)

What is claimed is:
1. An activated poly(ethylene glycol) derivative having the structure:
R--CH.sub.2 CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --Y
wherein n equals 5 to 3,000, Y is --SO2 --CH═CH2, and R is selected from the group consisting of HO--, H3 CO--, X--CH2 --CH2 --SO2 --, where X is halogen, and CH2 ═CH--SO2 --.
2. The activated poly(ethylene glycol) derivative of claim 1 wherein X is chlorine.
3. The activated poly(ethylene glycol) derivative of claim 1 wherein n equals about 5 to 2200.
4. The activated poly(ethylene glycol), derivative of claim 1 wherein n equals about 34 to 1100.
5. The activated poly(ethylene glycol) derivative of claim 1 wherein n equals about 45 to 110.
6. The activated polymer of claim 1 wherein said activated polymer is stable in aqueous environments of pH about 11 or less.
7. The activated polymer of claim 1 wherein said activated polymer is selective for reaction with thiol moieties at pH conditions of about 9 or less.
8. The activated polymer of claim 1 wherein said activated polymer is stable in reducing environments.
9. The activated polymer of claim 1 wherein said activated polymer is infinitely soluble in water.
10. An activated poly(ethylene glycol) derivative having the structure:
CH.sub.3 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH═CH.sub.2
wherein n equals 5 to 3,000.
11. An activated poly(ethylene glycol) derivative having the structure:
CH.sub.2 ═CH--SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2)hd n--SO.sub.2 --CH═CH.sub.2
wherein n equals 5 to 3,000.
12. A hydrolytically stable, biologically active conjugate that is the reaction product of 1) at least one biologically active molecule having the structure W-SH, wherein W- is a biologically active moiety and --SH is a reactive thiol moiety, and 2) a poly(ethylene glycol) derivative activated with one or more sulfone moieties and having the structure:
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --Y
wherein n equals 5 to 3,000, Y is --SO2 --CH═CH2, and R is selected from the group consisting of HO--, H3 CO--, X--CH2 --CH2 --SO2 --, wherein X is halogen, and CH2 ═CH`SO2 --, and wherein said reactive thiol moiety is linked to said at least one active sulfone moiety.
13. The conjugate of claim 12 wherein said biologically active molecule is protein and said reactive thiol moiety is contained within a cysteine moiety of said protein.
14. The conjugate of claim 12 wherein said conjugate has the following structure:
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-W
wherein n equals 5 to 3,000 and R is selected from the group consisting of HO-- and H3 CO--.
15. The biologically active conjugate of claim 12 wherein said conjugate has the following structure:
W--S--CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-W
wherein n equals 5 to 3,000.
16. The biologically active conjugate of claim 12 wherein said conjugate has the following structure:
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein
wherein n equals 5 to 3,000 and R is selected from the group consisting of HO-- and H3 CO--.
17. The biologically active conjugate of claim 12 wherein said conjugate has the following structure:
protein-S--CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 S-protein
wherein n equals 5 to 3,000.
18. A method for preparing poly(ethylene glycol) vinyl sulfone comprising the steps of:
(a) reacting poly(ethylene glycol) having at least one active hydroxyl moiety with a compound to form either an ester or a halide substituted poly(ethylene glycol);
(b) reacting the ester or a halide substituted poly(ethylene glycol) of step (a) with mercaptoethanol to substitute the mercaptoethanol radical for the ester or halide moiety;
(c) reacting the mercaptoethanol substituted poly(ethylene glycol) of step (b) with an oxidizing agent to oxide sulfur in the mercaptoethanol moiety to sulfone;
(d) reacting the sulfone of step (c) with a compound to convert the hydroxyl of the mercaptoethanol moiety to an ester or halide moiety;
(e) reacting the ethyl sulfone of step (d) with base to form poly(ethylene glycol) vinyl sulfone.
19. The method of claim 18 further comprising the steps of isolating the poly(ethylene glycol) vinyl sulfone.
20. The method of claim 18 wherein the halide of step (d) is chlorine and the product of step (d) is poly(ethylene glycol) chloroethyl sulfone, and wherein the method further comprises the step of isolating the poly(ethylene glycol chloroethyl sulfone by dissolving the chloroethyl sulfone in dichloromethane, precipitating the chloroethyl sulfone in ethyl ether, and recrystallizing the precipitate from ethyl acetate.
21. The method of claim 20 further comprising the steps of dissolving the poly(ethylene gylcol) chloroethyl sulfone crystals in an organic solvent prior to reaction with base to form poly(ethylene glycol) vinyl sulfone, and isolating the poly(ethylene glycol) vinyl sulfone product by filtering to remove the base and evaporating the solvent.
22. A method for preparing a biologically active conjugate of at least one biologically active molecule having the structure W-SH, wherein W-- is a biologically active moiety and --SH is an active thiol moiety, and an activated poly(ethylene glycol) derivative having at least one active sulfone moiety, the activated poly(ethylene glycol) derivative having the structure R--CH2 CH2 --(OCH2 CH2)n --Y, wherein n equals 5 to 3,000, Y is --SO2 --CH═CH2, and R is selected from the group consisting of HO--, H3 CO--, X--CH2 --CH2 --SO2 --, wherein X is halogen, and CH2 ═CH--SO2 --, said method comprising the steps of reacting the biologically active molecule with the activated poly(ethylene glycol) derivative and forming a linkage between the active thiol moiety and the at least one active sulfone moiety of the poly(ethylene glycol).
23. The method of claim 22 wherein W is protein.
24. A method for preparing a biologically active conjugate having the structure
protein-S--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein,
wherein n equals 5 to 3,000, the method comprising the steps of 1) reacting at least one protein having an active thiol moiety with a sulfone activated poly(ethylene glycol) derivative having the structure R--CH2 CH2 --(OCH2 CH2)n --SO2 --CH═CH2, wherein R is selected from the group consisting of CH2 ═CH--SO2 -- and X--CH2 --CH2 --SO2 --, and wherein X is halogen, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moieties of the activated polymer.
25. A method for preparing a biologically active conjugate having the structure
H.sub.3 CO--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein
wherein n equals 5 to 3,000, the method comprising the steps of 1) reacting a protein having an active thiol moiety with an activated poly(ethylene glycol) derivative having the structure H2 CO--CH2 --CH2 --(OCH2 CH2)n --SO2 --CH═CH2, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moiety of the activated polymer.
US08/151,4811993-11-121993-11-12Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and moleculesExpired - LifetimeUS5446090A (en)

Priority Applications (33)

Application NumberPriority DateFiling DateTitle
US08/151,481US5446090A (en)1993-11-121993-11-12Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
DK95901226TDK0728155T3 (en)1993-11-121994-11-14 Water-soluble active sulfones of poly (ethylene glycol)
EE9600128AEE03448B1 (en)1993-11-121994-11-14 Water-soluble active poly (ethylene glycol) sulfones and methods for their preparation
BR9408048ABR9408048A (en)1993-11-121994-11-14 Water-soluble and hydrolytically stable isolates of active poly (ethylene glycol) and related polymers for the modification of surfaces and molecules
UA96062250AUA58481C2 (en)1993-11-121994-11-14A water soluble hydrolitically stable activated polymer, a method for preparing the activated polyethylene glycol (variants), a biologically active conjugate
JP07514031AJP3114998B2 (en)1993-11-121994-11-14 Active sulfones of isolable, water-soluble and hydrolytically stable poly (ethylene glycol) and related polymers for surface and molecular modification
ES95901226TES2173943T3 (en)1993-11-121994-11-14 WATER SOLUBLE POLYETHYLENGLYCOL ACTIVE SULPHONES
CA002176203ACA2176203C (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol)
PL94314298APL180149B1 (en)1993-11-121994-11-14 method for producing activated poly(ethylene glycol), biologically active conjugate, method for producing poly(ethylene glycol) conjugate, method for producing vinyl sulfone and method for producing haloethyl sulfone
KR1019960702507AKR100225746B1 (en)1993-11-121994-11-14 Poly (ethylene glycol) with water soluble active sulfone
HU9601253AHU225649B1 (en)1993-11-121994-11-14Isolable, water soluble, hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers to modify surfaces and molecules, process for producing thereof, biologically active conjugates thereof and process for producing said conjugates
RU96113123/04ARU2176253C2 (en)1993-11-121994-11-14Water-soluble hydrolytically stable activated polymer, method of synthesis of activated polyethylene glycol (variants), biologically active conjugate
SK608-96ASK284527B6 (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol) and process of their preparation
DE69430317TDE69430317T2 (en)1993-11-121994-11-14 WATER-SOLUBLE ACTIVE SULFONES FROM POLYETHYLENE GLYCOLES
CZ19961375ACZ295640B6 (en)1993-11-121994-11-14Water soluble, activated and hydrolytically stable polymer, use thereof, hydrolytically stable, biologically active conjugate and use thereof, biological material, method for synthesizing the water soluble, activated polymer and process for preparing the biologically active conjugate
RO96-00959ARO118434B1 (en)1993-11-121994-11-14Poly(ethylene glycolsulphone) derivatives and process for preparing said derivatives and biological conjugates containing the same
AT95901226TATE215577T1 (en)1993-11-121994-11-14 WATER SOLUBLE ACTIVE SULFONES OF POLYETHYLENE GLYCOLES
CN94194460ACN1085689C (en)1993-11-121994-11-14 Separable, water-soluble and hydrolytically stable reactive polyethylene glycol sulfone and related polymers for surface and molecular modification
ROA200000307ARO121855B1 (en)1993-11-121994-11-14 DERIVATIVES OF POLYETHYLENGLICYL SULFON AND PROCESSES FOR THEIR OBTAINING
AU10548/95AAU687937B2 (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol)
EP01122161AEP1176160A3 (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol)
EP95901226AEP0728155B1 (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol)
NZ276313ANZ276313A (en)1993-11-121994-11-14Sulphone-substituted polyethers and their use as conjugate carriers with bioactive materials
PCT/US1994/013013WO1995013312A1 (en)1993-11-121994-11-14Water soluble active sulfones of poly(ethylene glycol)
US08/473,734US5739208A (en)1993-11-121995-06-07Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
BG100568ABG63399B1 (en)1993-11-121996-05-06 ACTIVE SOLFONIC POLYMER DERIVATIVES, IN PARTICULAR TO POLYETHYLENE GLYCOL, METHODS FOR THEIR PREPARATION AND APPLICATION
FI962004AFI117441B (en)1993-11-121996-05-10 Water-soluble active polyethylene glycol sulfones
NO19961918ANO315377B1 (en)1993-11-121996-05-10 Pharmaceutical composition and process for synthesizing poly (ethylene glycol) vinyl sulfone
US09/027,679US5900461A (en)1993-11-121998-02-23Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US09/294,188US6610281B2 (en)1993-11-121999-04-19Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules
HK02104035.7AHK1042312A1 (en)1993-11-122002-05-30Water soluble active sulfones of poly(ethylene glycol)
US10/647,621US6894025B2 (en)1993-11-122003-08-25Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety
US11/112,118US7214366B2 (en)1993-11-122005-04-22Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US08/151,481US5446090A (en)1993-11-121993-11-12Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US08/473,734DivisionUS5739208A (en)1993-11-121995-06-07Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Publications (1)

Publication NumberPublication Date
US5446090Atrue US5446090A (en)1995-08-29

Family

ID=22538958

Family Applications (6)

Application NumberTitlePriority DateFiling Date
US08/151,481Expired - LifetimeUS5446090A (en)1993-11-121993-11-12Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US08/473,734Expired - LifetimeUS5739208A (en)1993-11-121995-06-07Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US09/027,679Expired - LifetimeUS5900461A (en)1993-11-121998-02-23Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US09/294,188Expired - Fee RelatedUS6610281B2 (en)1993-11-121999-04-19Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules
US10/647,621Expired - Fee RelatedUS6894025B2 (en)1993-11-122003-08-25Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety
US11/112,118Expired - Fee RelatedUS7214366B2 (en)1993-11-122005-04-22Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Family Applications After (5)

Application NumberTitlePriority DateFiling Date
US08/473,734Expired - LifetimeUS5739208A (en)1993-11-121995-06-07Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US09/027,679Expired - LifetimeUS5900461A (en)1993-11-121998-02-23Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US09/294,188Expired - Fee RelatedUS6610281B2 (en)1993-11-121999-04-19Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules
US10/647,621Expired - Fee RelatedUS6894025B2 (en)1993-11-122003-08-25Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety
US11/112,118Expired - Fee RelatedUS7214366B2 (en)1993-11-122005-04-22Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Country Status (26)

CountryLink
US (6)US5446090A (en)
EP (2)EP1176160A3 (en)
JP (1)JP3114998B2 (en)
KR (1)KR100225746B1 (en)
CN (1)CN1085689C (en)
AT (1)ATE215577T1 (en)
AU (1)AU687937B2 (en)
BG (1)BG63399B1 (en)
BR (1)BR9408048A (en)
CA (1)CA2176203C (en)
CZ (1)CZ295640B6 (en)
DE (1)DE69430317T2 (en)
DK (1)DK0728155T3 (en)
EE (1)EE03448B1 (en)
ES (1)ES2173943T3 (en)
FI (1)FI117441B (en)
HK (1)HK1042312A1 (en)
HU (1)HU225649B1 (en)
NO (1)NO315377B1 (en)
NZ (1)NZ276313A (en)
PL (1)PL180149B1 (en)
RO (2)RO121855B1 (en)
RU (1)RU2176253C2 (en)
SK (1)SK284527B6 (en)
UA (1)UA58481C2 (en)
WO (1)WO1995013312A1 (en)

Cited By (274)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0758906A1 (en)*1994-06-141997-02-26Tadahiko KohnoPegylation reagents and compounds formed therewith
US5672662A (en)*1995-07-071997-09-30Shearwater Polymers, Inc.Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1998051336A1 (en)*1997-05-151998-11-19Theratech, Inc.Targeted delivery to t lymphocytes
US6066673A (en)*1998-03-122000-05-23The Procter & Gamble CompanyEnzyme inhibitors
US6072040A (en)*1996-10-152000-06-06Medical Analysis Systems, Inc.Stabilized conjugates of uncomplexed subunits of multimeric proteins
US6129928A (en)*1997-09-052000-10-10Icet, Inc.Biomimetic calcium phosphate implant coatings and methods for making the same
US6143866A (en)*1989-07-182000-11-07Amgen, Inc.Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO2000078285A1 (en)*1999-06-182000-12-28University Of Medicine And Dentistry Of New JerseyControlled release of therapeutics by in-situ entrapment by matrix cross-linking
US6284246B1 (en)1997-07-302001-09-04The Procter & Gamble Co.Modified polypeptides with high activity and reduced allergenicity
US6303119B1 (en)1999-09-222001-10-16The Procter & Gamble CompanyPersonal care compositions containing subtilisin enzymes bound to water insoluble substrates
US6306820B1 (en)1996-12-062001-10-23Amgen Inc.Combination therapy using a TNF binding protein for treating TNF-mediated diseases
US6410017B1 (en)1998-09-222002-06-25The Procter & Gamble CompanyPersonal care compositions containing active proteins tethered to a water insoluble substrate
US20020114775A1 (en)*1996-09-232002-08-22Incept LlcCrosslinking agents and methods of use
US6495136B1 (en)1998-03-262002-12-17The Procter & Gamble CompanyProteases having modified amino acid sequences conjugated to addition moieties
US20030044468A1 (en)*2001-03-202003-03-06Francesco CellesiTwo-phase processing of thermosensitive polymers for use as biomaterials
WO2003018665A1 (en)*2001-08-222003-03-06Bioartificial Gel Technologies Inc.Process for the preparation of activated polyethylene glycols
US6538104B2 (en)2001-04-272003-03-25Medical Analysis Systems, Inc.Stabilization of cardiac troponin I subunits and complexes
US20030059906A1 (en)*2000-10-192003-03-27Hubbell Jeffrey A.Block copolymers for multifunctional self-assembled systems
US6566115B1 (en)1999-07-222003-05-20The Procter & Gamble CompanyProtease conjugates having sterically protected clip sites
US6569663B1 (en)1998-03-262003-05-27The Procter & Gamble CompanySerine protease variants having amino acid substitutions
US6586224B1 (en)1999-07-222003-07-01The Procter & Gamble CompanySubtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6586223B1 (en)1999-07-222003-07-01The Procter & Gamble CompanySubtilisin protease variants having amino acid substitutions in defined epitope regions
US20030157163A1 (en)*1998-09-082003-08-21Liang-Chang DongDosage form comprising therapeutic formulation
US20030162841A1 (en)*1998-12-042003-08-28InceptBiocompatible crosslinked polymers
US20030179692A1 (en)*2002-03-192003-09-25Yoshitaka OhotomoStorage medium
US20030180252A1 (en)*1997-11-102003-09-25Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro Mabs
US20030191291A1 (en)*2000-09-082003-10-09Kochendoerfer Gerd G.Synthetic erythropoiesis stimulating proteins
US6632457B1 (en)1998-08-142003-10-14Incept LlcComposite hydrogel drug delivery systems
US20030220245A1 (en)*2000-06-022003-11-27Hubbell Jeffrey AConjugate addition reactions for the controlled delivery of pharmaceutical active compounds
US6693083B2 (en)1997-08-052004-02-17Watson Pharmaceuticals, Inc.Conjugates targeted to the interleukin-2 receptor
US6706289B2 (en)2000-10-312004-03-16Pr Pharmaceuticals, Inc.Methods and compositions for enhanced delivery of bioactive molecules
US20040077835A1 (en)*2001-07-122004-04-22Robin OffordChemokine receptor modulators, production and use
US20040087778A1 (en)*1998-10-232004-05-06Amgen Inc.Modified peptides as therapeutic agents
US20040126361A1 (en)*2002-12-262004-07-01Mountain View Pharmaceuticals, Inc.Polymer conjugates of interferon-beta with enhanced biological potency
US20040136956A1 (en)*2002-09-052004-07-15Barker Nicholas P.Asialo-interferons and the treatment of liver cancer
US20040136952A1 (en)*2002-12-262004-07-15Mountain View Pharmaceuticals, Inc.Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US20040136955A1 (en)*2002-09-052004-07-15Barker Nicholas PModified asialo-interferons and uses thereof
WO2004061094A1 (en)2002-12-302004-07-22Gryphon Therapeutics, Inc.Water-soluble thioester and selenoester compounds and methods for making and using the same
WO2004063250A1 (en)*2003-01-062004-07-29Nektar Therapeutics Al, CorporationThiol-selective water-soluble polmer derivatives
US6818435B2 (en)2000-05-152004-11-16Tecan Trading AgMicrofluidics devices and methods for performing cell based assays
US20040249576A1 (en)*2003-03-312004-12-09XencorMethods for rational pegylation of proteins
US20040268425A1 (en)*2003-03-052004-12-30Deliatroph Pharmaceuticals, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050036978A1 (en)*2002-09-092005-02-17Antoni KozlowskiMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US20050048626A1 (en)*2003-01-062005-03-03Xencor, Inc.BAFF variants and methods thereof
US20050089970A1 (en)*2000-07-122005-04-28Bradburne James A.Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
US20050089515A1 (en)*2003-08-292005-04-28Dyax Corp.Poly-pegylated protease inhibitors
US20050114037A1 (en)*2003-03-312005-05-26Xencor, Inc.Methods for rational pegylation of proteins
US20050130892A1 (en)*2003-03-072005-06-16Xencor, Inc.BAFF variants and methods thereof
US6908757B1 (en)1998-03-262005-06-21The Procter & Gamble CompanySerine protease variants having amino acid deletions and substitutions
US20050175584A1 (en)*2004-01-282005-08-11Paciotti Giulio F.Functionalized colloidal metal compositions and methods
US6946128B1 (en)1999-07-222005-09-20The Procter & Gamble CompanyProtease conjugates having sterically protected epitope regions
US20050221443A1 (en)*2003-01-062005-10-06Xencor, Inc.Tumor necrosis factor super family agonists
US20050228187A1 (en)*2004-03-052005-10-13Marie-Pierre FaureProcess for the preparation of activated polyethylene glycols
US20050250678A1 (en)*2004-01-082005-11-10Neose Technologies, Inc.O-linked glycosylation of peptides
US20050250696A1 (en)*1996-07-092005-11-10Fisher Eric FTruncated soluble tumor necrosis factor type-I and type-II receptors
US20050260186A1 (en)*2003-03-052005-11-24Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050261232A1 (en)*2004-04-132005-11-24Quintessence Biosciences, Inc.Non-natural ribonuclease conjugates as cytotoxic agents
US20060014248A1 (en)*2003-01-062006-01-19Xencor, Inc.TNF super family members with altered immunogenicity
US20060019347A1 (en)*2004-07-212006-01-26Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006009901A2 (en)2004-06-182006-01-26Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US20060104968A1 (en)*2003-03-052006-05-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20060127352A1 (en)*1999-02-012006-06-15Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US20060135586A1 (en)*2004-12-212006-06-22Antoni KozlowskiStabilized polymeric thiol reagents
US20060135427A1 (en)*2004-12-222006-06-22Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7118737B2 (en)2000-09-082006-10-10Amylin Pharmaceuticals, Inc.Polymer-modified synthetic proteins
US20070071764A1 (en)*2005-04-222007-03-29Sullivan John KToxin peptide therapeutic agents
US20070137573A1 (en)*2005-12-212007-06-21Arnold KholodenkoApparatus for an optimized plasma chamber grounded electrode assembly
US20070160572A1 (en)*1998-11-102007-07-12Lawrence TamarkinColloidal metal compositions and methods
WO2007084460A2 (en)2006-01-182007-07-26Qps, LlcPharmaceutical compositions with enhanced stability
WO2007149594A2 (en)2006-06-232007-12-27Quintessence Biosciences, Inc.Modified ribonucleases
WO2008030558A2 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
US20080097083A1 (en)*2004-02-022008-04-24Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US20080095755A1 (en)*2006-07-172008-04-24Quintessence Biosciences, Inc.Methods and compositions for the treatment of cancer
US20080108792A1 (en)*2005-06-032008-05-08Ambrx, Inc.Human Interferon Molecules and Their Uses
WO2008060780A2 (en)2006-10-042008-05-22Novo Nordisk A/SGlycerol linked pegylated sugars and glycopeptides
US20080153745A1 (en)*2005-08-182008-06-26Ambrx, In.Compositions of tRNA and uses thereof
WO2008095063A1 (en)2007-01-312008-08-07Dana-Farber Cancer Institute, Inc.Stabilized p53 peptides and uses thereof
US20080255026A1 (en)*2005-05-252008-10-16Glycopegylated Factor 1XGlycopegylated Factor Ix
US20080255045A1 (en)*2007-03-302008-10-16Ambrx, Inc.Modified FGF-21 Polypeptides and Their Uses
US20080253987A1 (en)*2007-04-132008-10-16Kuros Biosurgery AgPolymeric tissue sealant
US20080260802A1 (en)*1996-09-232008-10-23Sawhney Amarpreet SBiocompatible hydrogels made with small molecule precursors
US20080317670A1 (en)*2005-12-142008-12-25Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
US20090000924A1 (en)*2007-06-292009-01-01Harley-Davidson Motor Company Group, Inc.Integrated ignition and key switch
US20090017097A1 (en)*2007-07-092009-01-15Sawhney Amarpreet SHydrogel polymeric compositions and methods
US20090030451A1 (en)*2005-02-092009-01-29Hadba Ahmad RSynthetic Sealants
US20090047349A1 (en)*2007-08-132009-02-19Confluent Surgical, Inc.Drug delivery device
US20090075887A1 (en)*2007-08-212009-03-19Genzyme CorporationTreatment with Kallikrein Inhibitors
EP2042196A2 (en)2001-10-102009-04-01Neose Technologies, Inc.Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US20090098101A1 (en)*2007-10-082009-04-16Quintessence Biosciences, Inc.Compositions and methods for ribonuclease-based therapeutics
US20090104114A1 (en)*2007-09-212009-04-23Cytimmune Sciences, Inc.Nanotherapeutic Colloidal Metal Compositions and Methods
EP2055189A1 (en)2003-04-092009-05-06Neose Technologies, Inc.Glycopegylation methods and proteins/peptides produced by the methods
US20090118181A1 (en)*2007-05-222009-05-07Walker Kenneth WCompositions and methods for producing bioactive fusion proteins
US20090123367A1 (en)*2003-03-052009-05-14DelfmemsSoluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20090137736A1 (en)*2005-11-082009-05-28Ambrx, Inc.Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides
WO2009067636A2 (en)2007-11-202009-05-28Ambrx, Inc.Modified insulin polypeptides and their uses
US20090148908A1 (en)*2007-11-082009-06-11Paciotti Giulio FCompositions and methods for generating antibodies
US20090208454A1 (en)*2007-05-022009-08-20Ambrx, Inc.Modified interferon beta polypeptides and their uses
US20090227981A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090227689A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090281028A1 (en)*2006-10-252009-11-12Sullivan John KOSK1 peptide analogs and pharmaceutical compositions
US7642340B2 (en)2003-03-312010-01-05Xencor, Inc.PEGylated TNF-α variant proteins
US20100010194A1 (en)*2006-11-302010-01-14Nektar Therapeutics Al, CorporationMethod for Preparing a Polymer Conjugate
WO2010011735A2 (en)2008-07-232010-01-28Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
US20100034769A1 (en)*2002-03-222010-02-11Kuros Biosurgery, AGCompositions for tissue augmentation
US20100093608A1 (en)*2008-09-262010-04-15Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US7736872B2 (en)2004-12-222010-06-15Ambrx, Inc.Compositions of aminoacyl-TRNA synthetase and uses thereof
US20100159586A1 (en)*2006-09-082010-06-24Ambrx, Inc.Hybrid Suppressor tRNA for Vertebrate Cells
US20100159585A1 (en)*2006-09-082010-06-24Ambrx, Inc.Suppressor tRNA Transcription in Vertebrate Cells
US7744912B1 (en)1999-02-012010-06-29Eidgenossische Technische Hochschule ZurichBiomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2010077297A1 (en)2008-12-092010-07-08Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
US20100183625A1 (en)*2009-01-062010-07-22Dyax Corp.Treatment of Mucositis with Kallikrein Inhibitors
US20100222407A1 (en)*2005-05-312010-09-02Tatiana SeguraTriblock copolymers for cytoplasmic delivery of gene-based drugs
US7795210B2 (en)2001-10-102010-09-14Novo Nordisk A/SProtein remodeling methods and proteins/peptides produced by the methods
US7803777B2 (en)2003-03-142010-09-28Biogenerix AgBranched water-soluble polymers and their conjugates
US7842661B2 (en)2003-11-242010-11-30Novo Nordisk A/SGlycopegylated erythropoietin formulations
WO2010144629A1 (en)2009-06-092010-12-16Prolong Pharmaceuticals, LLCHemoglobin compositions
US20100330060A1 (en)*2003-12-032010-12-30Novo Nordisk A/SGlycopegylated factor ix
US20110014118A1 (en)*2007-09-212011-01-20Lawrence TamarkinNanotherapeutic colloidal metal compositions and methods
EP2279756A2 (en)2005-04-052011-02-02Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A.Method for shielding functional sites or epitopes on proteins
WO2011015634A2 (en)2009-08-052011-02-10Pieris AgControlled release formulations of lipocalin muteins
EP2284191A2 (en)2004-12-222011-02-16Ambrx, Inc.Process for the preparation of hGH
WO2011034604A2 (en)2009-09-172011-03-24Baxter Healthcare, S.A.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US20110086801A1 (en)*2002-06-072011-04-14Dyax Corp.Prevention and reduction of blood loss
US7932364B2 (en)2003-05-092011-04-26Novo Nordisk A/SCompositions and methods for the preparation of human growth hormone glycosylation mutants
US7947473B2 (en)2004-12-222011-05-24Ambrx, Inc.Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7951614B2 (en)2003-12-022011-05-31Cytimmune Sciences, Inc.Methods and compositions for the production of monoclonal antibodies
EP2327723A2 (en)2003-10-102011-06-01Xencor, Inc.Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7956032B2 (en)2003-12-032011-06-07Novo Nordisk A/SGlycopegylated granulocyte colony stimulating factor
US20110136723A1 (en)*2008-07-212011-06-09Polytherics LimitedNovel reagents and method for conjugating biological molecules
US20110144307A1 (en)*2005-11-162011-06-16Ambrx, Inc.Methods and Compositions Comprising Non-Natural Amino Acids
US20110195483A1 (en)*2008-09-262011-08-11Ambrx, Inc.Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines
US20110200611A1 (en)*2010-01-062011-08-18Dyax Corp.Plasma kallikrein binding proteins
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
US8008252B2 (en)2001-10-102011-08-30Novo Nordisk A/SFactor VII: remodeling and glycoconjugation of Factor VII
US8029782B2 (en)2008-10-012011-10-04Quintessence Biosciences, Inc.Therapeutic ribonucleases
US20110269942A1 (en)*2007-08-092011-11-03Daiichi Sankyo Company, LimitedAntibodies modified with hydrophobic molecule
US8053410B2 (en)2002-06-212011-11-08Novo Nordisk Health Care A/GPegylated factor VII glycoforms
EP2386571A2 (en)2005-04-082011-11-16BioGeneriX AGCompositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8076292B2 (en)2001-10-102011-12-13Novo Nordisk A/SFactor VIII: remodeling and glycoconjugation of factor VIII
WO2012012300A2 (en)2010-07-202012-01-26Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
WO2012024452A2 (en)2010-08-172012-02-23Ambrx, Inc.Modified relaxin polypeptides and their uses
US8137989B2 (en)1994-03-182012-03-20Cytimmune Sciences, Inc.Method for delivering a cytokine using a colloidal metal
WO2012065181A2 (en)2010-11-122012-05-18Dana Farber Cancer Institute, Inc.Cancer therapies and diagnostics
US8207112B2 (en)2007-08-292012-06-26Biogenerix AgLiquid formulation of G-CSF conjugate
WO2012109387A1 (en)2011-02-082012-08-16Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US8268967B2 (en)2004-09-102012-09-18Novo Nordisk A/SGlycopegylated interferon α
WO2012125973A2 (en)2011-03-162012-09-20Amgen Inc.Potent and selective inhibitors of nav1.3 and nav1.7
EP2514757A2 (en)2005-01-102012-10-24BioGeneriX AGGlycopegylated granulocyte colony stimulating factor
US8318154B2 (en)2008-04-282012-11-27Halozyme, Inc.Super fast-acting insulin compositions
WO2012174478A2 (en)2011-06-172012-12-20Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en)2011-06-172012-12-20Halozyme, Inc.Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
WO2013006706A1 (en)2011-07-052013-01-10Bioasis Technologies Inc.P97-antibody conjugates and methods of use
EP2548967A2 (en)2006-09-212013-01-23The Regents of The University of CaliforniaAldehyde tags, uses thereof in site-specific protein modification
WO2013040501A1 (en)2011-09-162013-03-21Pharmathene, Inc.Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US8409606B2 (en)2009-02-122013-04-02Incept, LlcDrug delivery through hydrogel plugs
EP2586456A1 (en)2004-10-292013-05-01BioGeneriX AGRemodeling and glycopegylation of fibroblast growth factor (FGF)
WO2013063155A2 (en)2011-10-242013-05-02Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP2599502A2 (en)2003-04-112013-06-05PR Pharmaceuticals Inc.Method for preparation of site-specific protein conjugates
WO2013102211A2 (en)2011-12-292013-07-04Walensky Loren DStabilized antiviral fusion helices
WO2013151774A1 (en)2012-04-042013-10-10Halozyme, Inc.Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
EP2662090A1 (en)2008-04-142013-11-13Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2013185115A1 (en)2012-06-082013-12-12Sutro Biopharma, Inc.Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8633157B2 (en)2003-11-242014-01-21Novo Nordisk A/SGlycopegylated erythropoietin
WO2014022515A1 (en)2012-07-312014-02-06Bioasis Technologies, Inc.Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US8663629B2 (en)1994-01-112014-03-04Dyax Corp.Kallikrein-binding “kunitz domain” proteins and analogues thereof
WO2014036492A1 (en)2012-08-312014-03-06Sutro Biopharma, Inc.Modified amino acids comprising an azido group
US8685417B2 (en)2006-12-202014-04-01Arkema, Inc.Polymer encapsulation and/or binding
WO2014062856A1 (en)2012-10-162014-04-24Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US8716239B2 (en)2001-10-102014-05-06Novo Nordisk A/SGranulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF
US8716240B2 (en)2001-10-102014-05-06Novo Nordisk A/SErythropoietin: remodeling and glycoconjugation of erythropoietin
US8716225B2 (en)2004-09-272014-05-06Dyax Corp.Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2014099984A1 (en)2012-12-202014-06-26Amgen Inc.Apj receptor agonists and uses thereof
US8791070B2 (en)2003-04-092014-07-29Novo Nordisk A/SGlycopegylated factor IX
US8791066B2 (en)2004-07-132014-07-29Novo Nordisk A/SBranched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
WO2014144148A1 (en)2013-03-152014-09-18Dana-Farber Cancer Institute, Inc.Stabilized sos1 peptides
WO2014144768A2 (en)2013-03-152014-09-18Dana-Farber Cancer Institute, Inc.Bh4 stabilized peptides and uses thereof
US8841439B2 (en)2005-11-032014-09-23Novo Nordisk A/SNucleotide sugar purification using membranes
WO2014151369A2 (en)2013-03-152014-09-25Dana-Farber Cancer Institute, Inc.Stabilized ezh2 peptides
WO2014160438A1 (en)2013-03-132014-10-02Bioasis Technologies Inc.Fragments of p97 and uses thereof
WO2014165277A2 (en)2013-03-122014-10-09Amgen Inc.POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP2805965A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified bovine somatotropin polypeptides and their uses
US8911967B2 (en)2005-08-192014-12-16Novo Nordisk A/SOne pot desialylation and glycopegylation of therapeutic peptides
US8916360B2 (en)2003-11-242014-12-23Novo Nordisk A/SGlycopegylated erythropoietin
WO2015003167A1 (en)2013-07-032015-01-08Halozyme, Inc.Thermally stable ph20 hyaluronidase variants and uses thereof
WO2015006555A2 (en)2013-07-102015-01-15Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8961501B2 (en)2010-09-172015-02-24Incept, LlcMethod for applying flowable hydrogels to a cornea
US8969532B2 (en)2006-10-032015-03-03Novo Nordisk A/SMethods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2015031673A2 (en)2013-08-282015-03-05Bioasis Technologies Inc.Cns-targeted conjugates having modified fc regions and methods of use thereof
US8980608B2 (en)2012-03-302015-03-17The Board Of Regents Of The University Of OklahomaHigh molecular weight heparosan polymers and methods of production and use thereof
US9005598B2 (en)2009-03-042015-04-14Polytherics LimitedConjugated proteins and peptides
US9005625B2 (en)2003-07-252015-04-14Novo Nordisk A/SAntibody toxin conjugates
WO2015054658A1 (en)2013-10-112015-04-16Sutro Biopharma, Inc.Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015081282A1 (en)2013-11-272015-06-04Redwood Bioscience, Inc.Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9050304B2 (en)2007-04-032015-06-09Ratiopharm GmbhMethods of treatment using glycopegylated G-CSF
US9114144B2 (en)2002-06-072015-08-25Dyax Corp.Kallikrein-inhibitor therapies
US9150848B2 (en)2008-02-272015-10-06Novo Nordisk A/SConjugated factor VIII molecules
US9187532B2 (en)2006-07-212015-11-17Novo Nordisk A/SGlycosylation of peptides via O-linked glycosylation sequences
WO2015175774A1 (en)2014-05-142015-11-19Trustees Of Dartmouth CollegeDeimmunized lysostaphin and methods of use
US9205150B2 (en)2011-12-052015-12-08Incept, LlcMedical organogel processes and compositions
WO2015191781A2 (en)2014-06-102015-12-17Amgen Inc.Apelin polypeptides
US9266964B2 (en)2011-01-062016-02-23Dyax Corp.Method of treating hereditary angioedema using plasma kallikrein binding antibodies
US9271929B2 (en)2008-11-252016-03-01École Polytechnique Fédérale De Lausanne (Epfl)Block copolymers and uses thereof
WO2016033555A1 (en)2014-08-282016-03-03Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US9310374B2 (en)2012-11-162016-04-12Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
US9310627B2 (en)2013-11-152016-04-12Ocular Dynamics, LlcContact lens with a hydrophilic layer
WO2016061286A2 (en)2014-10-142016-04-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US9395468B2 (en)2012-08-272016-07-19Ocular Dynamics, LlcContact lens with a hydrophilic layer
US9434778B2 (en)2014-10-242016-09-06Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9447401B2 (en)2011-12-302016-09-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US9493499B2 (en)2007-06-122016-11-15Novo Nordisk A/SProcess for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP3103880A1 (en)2008-02-082016-12-14Ambrx, Inc.Modified leptin polypeptides and their uses
US9567386B2 (en)2010-08-172017-02-14Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
US9579390B2 (en)2012-11-122017-02-28Redwood Bioscience, Inc.Compounds and methods for producing a conjugate
EP3135690A1 (en)2012-06-262017-03-01Sutro Biopharma, Inc.Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9605078B2 (en)2012-11-162017-03-28The Regents Of The University Of CaliforniaPictet-Spengler ligation for protein chemical modification
US9775889B2 (en)2008-03-062017-10-03Halozyme, Inc.Methods of treatment of cellulite
US20170360994A1 (en)*2014-12-092017-12-21Tangible Science, LlcMedical device coating with a biocompatible layer
WO2018039545A2 (en)2016-08-262018-03-01Dana-Farber Cancer Institute, Inc.Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
US9993529B2 (en)2011-06-172018-06-12Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
WO2018170299A1 (en)2017-03-152018-09-20The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesInhibitors of prokaryotic gene transcription and uses thereof
WO2018237201A1 (en)2017-06-222018-12-27Catalyst Biosciences, Inc. MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE
WO2019018499A2 (en)2017-07-192019-01-24Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
US10226417B2 (en)2011-09-162019-03-12Peter JarrettDrug delivery systems and applications
US10266578B2 (en)2017-02-082019-04-23Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019118719A1 (en)2017-12-152019-06-20Dana-Farber Cancer Institute, Inc.Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
WO2019118893A1 (en)2017-12-152019-06-20Dana-Farber Cancer Institute, Inc.Stabilized peptide-mediated targeted protein degradation
WO2019133399A1 (en)2017-12-262019-07-04Becton, Dickinson And CompanyDeep ultraviolet-excitable water-solvated polymeric dyes
WO2019157131A1 (en)2018-02-072019-08-15Dana-Farber Cancer Institute, Inc.Cell-permeable stapled peptide modules for cellular delivery
WO2019178313A1 (en)2018-03-142019-09-19Dana-Farber Cancer Institute, Inc.Stabilized peptides for biomarker detection
US10421785B2 (en)2016-04-112019-09-24Bar-Ilan UniversityDelta receptor agonist peptides and use thereof
WO2019191482A1 (en)2018-03-302019-10-03Becton, Dickinson And CompanyWater-soluble polymeric dyes having pendant chromophores
US10464975B2 (en)2015-07-022019-11-05Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides
WO2019222435A1 (en)2018-05-162019-11-21Halozyme, Inc.Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020023300A1 (en)2018-07-222020-01-30Bioasis Technologies, Inc.Treatment of lymmphatic metastases
WO2020056066A1 (en)2018-09-112020-03-19Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en)2018-10-192020-04-23Ambrx, Inc.Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020131871A1 (en)*2018-12-192020-06-25Tangible Science, Inc.Systems and methods of treating a hydrogel-coated medical device
WO2020140101A1 (en)2018-12-282020-07-02Catalyst Biosciences, Inc.Modified urokinase-type plasminogen activator polypeptides and methods of use
US10711106B2 (en)2013-07-252020-07-14The University Of ChicagoHigh aspect ratio nanofibril materials
WO2020168017A1 (en)2019-02-122020-08-20Ambrx, Inc.Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2020215005A1 (en)2019-04-182020-10-22Dana-Farber Cancer Institute, Inc.Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
WO2021126827A1 (en)2019-12-162021-06-24Dana-Farber Cancer Institute, Inc.Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en)2019-12-202021-06-24Dana-Farber Cancer Institute, Inc.Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
US11046785B2 (en)2014-03-272021-06-29Takeda Pharmaceutical Company LimitedCompositions and methods for treatment of diabetic macular edema
US11078246B2 (en)2015-08-282021-08-03Dana-Farber Cancer Institute, Inc.Peptides binding to Bfl-1
WO2021178714A2 (en)2020-03-042021-09-10Dana-Farber Cancer Institute, Inc.ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
WO2021183832A1 (en)2020-03-112021-09-16Ambrx, Inc.Interleukin-2 polypeptide conjugates and methods of use thereof
US11142554B2 (en)2015-03-182021-10-12Massachusetts Institute Of TechnologySelective Mcl-1 binding peptides
WO2021216845A1 (en)2020-04-222021-10-28Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
WO2021222243A2 (en)2020-04-272021-11-04Dana-Farber Cancer Institute, Inc.Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
WO2021236526A1 (en)2020-05-182021-11-25Bioasis Technologies, Inc.Compositions and methods for treating lewy body dementia
US11198715B2 (en)2016-07-222021-12-14Massachusetts Institute Of TechnologySelective Bfl-1 peptides
WO2021255524A1 (en)2020-06-172021-12-23Bioasis Technologies, Inc.Compositions and methods for treating frontotemporal dementia
WO2022040596A1 (en)2020-08-202022-02-24Ambrx, Inc.Antibody-tlr agonist conjugates, methods and uses thereof
US11273202B2 (en)2010-09-232022-03-15Elanco Us Inc.Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11286299B2 (en)2018-09-172022-03-29Massachusetts Institute Of TechnologyPeptides selective for Bcl-2 family proteins
US11286307B2 (en)2015-12-112022-03-29Takeda Pharmaceutical Company LimitedPlasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2022081827A1 (en)2020-10-142022-04-21Dana-Farber Cancer Institute, Inc.Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2022098848A1 (en)2020-11-052022-05-12Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ebolavirus peptides and uses thereof
WO2022212899A1 (en)2021-04-032022-10-06Ambrx, Inc.Anti-her2 antibody-drug conjugates and uses thereof
WO2023039474A1 (en)2021-09-082023-03-16Dana-Farber Cancer Institute, Inc.Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
US11613744B2 (en)2018-12-282023-03-28Vertex Pharmaceuticals IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
EP4155349A1 (en)2021-09-242023-03-29Becton, Dickinson and CompanyWater-soluble yellow green absorbing dyes
WO2023215784A1 (en)2022-05-042023-11-09Dana-Farber Cancer Institute, Inc.Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2024007016A2 (en)2022-07-012024-01-04Beckman Coulter, Inc.Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en)2022-08-262024-02-29Beckman Coulter, Inc.Dhnt monomers and polymer dyes with modified photophysical properties
US11945846B2 (en)2016-02-292024-04-02Dana-Farber Cancer Institute, Inc.Stapled intracellular-targeting antimicrobial peptides to treat infection
WO2024196805A1 (en)2023-03-172024-09-26Beckman Coulter, Inc.Benzothienopyrrole cyanine dyes
US12102689B2 (en)2015-11-092024-10-01R.P. Scherer Technologies, LlcAnti-CD22 antibody-maytansine conjugates and methods of use thereof
WO2025064842A1 (en)2023-09-212025-03-27Beckman Coulter, Inc.Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
US12312437B2 (en)2016-04-152025-05-27Beckman Coulter, Inc.Photoactive macromolecules and uses thereof
US12344643B2 (en)2016-12-072025-07-01The University Of ChicagoCompositions and methods for inhibition of FOXP3
US12441775B2 (en)2022-08-292025-10-14Dana-Farber Cancer Institute, Inc.BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5583114A (en)1994-07-271996-12-10Minnesota Mining And Manufacturing CompanyAdhesive sealant composition
USRE38827E1 (en)1994-07-272005-10-113M Innovative Properties CompanyAdhesive sealant composition
JP4344404B2 (en)1996-02-092009-10-14アムジェン インコーポレイテッド Composition comprising interleukin-1 inhibitor and controlled release polymer
US5747639A (en)*1996-03-061998-05-05Amgen Boulder Inc.Use of hydrophobic interaction chromatography to purify polyethylene glycols
ATE406176T1 (en)1996-12-062008-09-15Amgen Inc IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES
US6743248B2 (en)1996-12-182004-06-01Neomend, Inc.Pretreatment method for enhancing tissue adhesion
US20030191496A1 (en)*1997-03-122003-10-09Neomend, Inc.Vascular sealing device with microwave antenna
US6371975B2 (en)1998-11-062002-04-16Neomend, Inc.Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20040176801A1 (en)*1997-03-122004-09-09Neomend, Inc.Pretreatment method for enhancing tissue adhesion
WO2001087925A2 (en)*2000-05-162001-11-22Bolder Biotechnology, Inc.Methods for refolding proteins containing free cysteine residues
US6168784B1 (en)1997-09-032001-01-02Gryphon SciencesN-terminal modifications of RANTES and methods of use
DK1411075T3 (en)1998-03-122008-10-27Nektar Therapeutics Al Corp Process for Preparation of Polymer Conjugates
US6458147B1 (en)1998-11-062002-10-01Neomend, Inc.Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6994686B2 (en)1998-08-262006-02-07Neomend, Inc.Systems for applying cross-linked mechanical barriers
ATE364654T1 (en)1998-08-282007-07-15Amylin Pharmaceuticals Inc POLYAMIDE CHAINS OF PRECISE LENGTH AND THEIR CONJUGATES WITH PROTEINS
US6949114B2 (en)1998-11-062005-09-27Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US7279001B2 (en)*1998-11-062007-10-09Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6830756B2 (en)*1998-11-062004-12-14Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en)*1998-11-062005-05-31Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US7008635B1 (en)*1999-09-102006-03-07Genzyme CorporationHydrogels for orthopedic repair
US7074878B1 (en)*1999-12-102006-07-11Harris J MiltonHydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en)1999-12-102002-02-19Shearwater CorporationHydrolytically degradable polymers and hydrogels made therefrom
ES2327606T3 (en)2000-01-102009-11-02Maxygen Holdings Ltd CONJUGATES OF G-CSF.
WO2001058935A2 (en)2000-02-112001-08-16Maxygen ApsFACTOR VII OR VIIa-LIKE MOLECULES
TW593427B (en)*2000-12-182004-06-21Nektar Therapeutics Al CorpSynthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en)*2000-12-182006-05-30Nektar Therapeutics Al, CorporationSegmented polymers and their conjugates
YU48703A (en)2001-02-272006-05-25Maxygen ApsNew interferon beta-like molecules
EP2939696B1 (en)2001-10-182016-03-09Nektar TherapeuticsPolymer conjugates of opioid antagonists
WO2003044231A1 (en)*2001-11-232003-05-30Simon FredrikssonMethod and kit for proximity probing with multivalent proximity probes
GEP20074024B (en)2002-01-182007-01-10Biogen Idec IncPolyalkylene glycol comprising a radical for conjugation of biologically active compound
DK1517710T3 (en)*2002-06-212011-07-18Novo Nordisk Healthcare Ag Pegylated factor VII glycoforms
US7034127B2 (en)*2002-07-022006-04-25Genzyme CorporationHydrophilic biopolymer-drug conjugates, their preparation and use
CN1312279C (en)*2002-11-072007-04-25连云港新阳医药有限公司Method for preparing elspar modilfied by carbowax
ES2352337T5 (en)*2003-01-062017-08-11Nektar Therapeutics Thiol-selective derivatives of a water soluble polymer
SI1596887T1 (en)2003-02-262022-05-31Nektar TherapeuticsPolymer-factor viii moiety conjugates
TW200510454A (en)2003-04-152005-03-16Smithkline Beecham CorpConjugates comprising human IL-18 and substitution mutants thereof
US20040249119A1 (en)*2003-06-052004-12-09Fox Martin EdwardNovel mPEG propionaldehyde precursor
GB0316294D0 (en)2003-07-112003-08-13Polytherics LtdConjugated biological molecules and their preparation
PL1656410T3 (en)2003-07-222010-08-31Nektar TherapeuticsMethod for preparing functionalized polymers from polymer alcohols
KR20120073370A (en)2003-09-172012-07-04넥타르 테라퓨틱스Multi-arm polymer prodrugs
JP4890253B2 (en)*2003-10-092012-03-07アンブレツクス・インコーポレイテツド Azide or acetylene-terminated water-soluble polymer
EP1673387B1 (en)2003-10-102010-09-15Novo Nordisk A/SIl-21 derivatives
US7524813B2 (en)*2003-10-102009-04-28Novo Nordisk Health Care AgSelectively conjugated peptides and methods of making the same
EP2633866A3 (en)2003-10-172013-12-18Novo Nordisk A/SCombination therapy
US8637650B2 (en)2003-11-052014-01-28Genovoxx GmbhMacromolecular nucleotide compounds and methods for using the same
MXPA06005732A (en)*2003-11-242006-08-17Neose Technologies IncGlycopegylated erythropoietin.
KR100580644B1 (en)*2004-02-162006-05-16삼성전자주식회사 Noncovalently Immobilized Biomolecules on Solid Substrates and Microarrays Prepared thereby
EP1725262B1 (en)*2004-03-152021-05-26Nektar TherapeuticsPolymer-based compositions and conjugates of hiv entry inhibitors
EP1735340A2 (en)*2004-03-172006-12-27Eli Lilly And CompanyGlycol linked fgf-21 compounds
EP2359842A1 (en)2004-07-142011-08-24University of Utah Research FoundationNetrin-related compositions and uses
EP1799713B1 (en)2004-09-232014-11-05VasGene Therapeutics, Inc.Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006047419A2 (en)*2004-10-252006-05-04Intezyne Technologies, IncorporatedHeterobifunctional poly(ethylene glycol) and uses thereof
EP1828224B1 (en)2004-12-222016-04-06Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7402730B1 (en)2005-02-032008-07-22Lexicon Pharmaceuticals, Inc.Knockout animals manifesting hyperlipidemia
US7365127B2 (en)*2005-02-042008-04-29Enzon Pharmaceuticals, Inc.Process for the preparation of polymer conjugates
EP1885403B1 (en)2005-04-122013-05-08Nektar TherapeuticsPoly(ethyleneglycol) conjugates of Lysostaphin
KR20080013878A (en)2005-04-182008-02-13노보 노르디스크 에이/에스 IL-21 variants
BRPI0609676A2 (en)2005-05-132011-10-18Lilly Co Eli compound of pegylated glp-1, and use thereof
US20060281712A1 (en)2005-06-142006-12-14Chi-Feng YenPyrimidine compounds
US8193206B2 (en)2005-06-142012-06-05Taigen Biotechnology Co., Ltd.Pyrimidine compounds
WO2006134173A2 (en)2005-06-172006-12-21Novo Nordisk Health Care AgSelective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ATE524509T1 (en)2005-07-182011-09-15Nektar Therapeutics BRANCHED FUNCTIONALIZED POLYMERS USING BRANCHED POLYOLS AS CORE
EP1968644B1 (en)2005-12-162012-06-27Nektar TherapeuticsPolymer conjugates of glp-1
US20070190127A1 (en)2005-12-302007-08-16Mingdong ZhouExtended release of neuregulin for improved cardiac function
JP5312050B2 (en)2006-02-212013-10-09ネクター セラピューティクス Split-type degradable polymers and composites produced therefrom
US9101670B2 (en)2006-04-072015-08-11Nektar TherapeuticsConjugates of an anti-TNF-α antibody
US8288339B2 (en)2006-04-202012-10-16Amgen Inc.GLP-1 compounds
CA2650035C (en)2006-04-272015-02-03Intezyne Technologies, Inc.Poly (ethylene glycol) containing chemically disparate endgroups
MX2008014685A (en)2006-05-242008-11-27Novo Nordisk Healthcare AgFactor ix analogues having prolonged in vivo half life.
WO2008002482A2 (en)*2006-06-232008-01-03Surmodics, Inc.Hydrogel-based joint repair system and method
WO2008049920A2 (en)2006-10-262008-05-02Novo Nordisk A/SIl-21 variants
AU2007325838B2 (en)2006-11-222013-09-19Bristol-Myers Squibb CompanyTargeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US7935796B2 (en)2006-12-082011-05-03Lexicon Pharmaceuticals, Inc.Monoclonal antibodies against ANGPTL3
WO2008076933A2 (en)2006-12-142008-06-26Bolder Biotechnology, Inc.Long acting proteins and peptides and methods of making and using the same
US8293214B2 (en)2006-12-192012-10-23Bracco Suisse S.A.Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
KR101160385B1 (en)2007-01-182012-07-10일라이 릴리 앤드 캄파니PEGYLATED Aß FAB
ATE516814T1 (en)2007-02-022011-08-15Bristol Myers Squibb Co 10FN3 DOMAIN FOR THE TREATMENT OF DISEASES ACCOMPANIED BY UNDESIRABLE ANGIOGENESIS
CN101361968B (en)2007-08-062011-08-03健能隆医药技术(上海)有限公司Use of interleukin-22 in treating fatty liver
MX2010004400A (en)2007-10-232010-05-20Nektar TherapeuticsHydroxyapatite-targeting multiarm polymers and conjugates made therefrom.
US20090123519A1 (en)*2007-11-122009-05-14Surmodics, Inc.Swellable hydrogel matrix and methods
CN101903439A (en)*2007-11-122010-12-01因特拉迪格姆公司 Heterobifunctional polyethylene glycol reagents
US20090226531A1 (en)*2008-03-072009-09-10Allergan, Inc.Methods and composition for intraocular delivery of therapeutic sirna
NZ588989A (en)2008-04-212012-03-30Taigen Biotechnology Co LtdHeterocyclic compounds comprising pyrimidine, piperazine and amine.
US20110135623A1 (en)*2008-05-162011-06-09Nektar TherapeuticsConjugates of a Cholinesterase Moiety and a Polymer
PE20091931A1 (en)2008-05-222009-12-31Bristol Myers Squibb Co MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS
AU2009282413B2 (en)2008-08-112014-07-17Nektar TherapeuticsMulti-arm polymeric alkanoate conjugates
US20110171164A1 (en)*2008-09-192011-07-14Nektar TherapeuticsPolymer conjugates of glp-2-like peptides
EP2340050A2 (en)*2008-09-192011-07-06Nektar TherapeuticsPolymer conjugates of aod-like peptides
US20110171312A1 (en)*2008-09-192011-07-14Nektar TherapeuticsModified therapeutic peptides, methods of their preparation and use
EP2334333A1 (en)*2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of v681-like peptides
EP2344199A1 (en)*2008-09-192011-07-20Nektar TherapeuticsPolymer conjugates of thymosin alpha 1 peptides
WO2010033224A1 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of kiss1 peptides
EP2340046A2 (en)*2008-09-192011-07-06Nektar TherapeuticsPolymer conjugates of ziconotide peptides
EP2341942A1 (en)2008-09-192011-07-13Nektar TherapeuticsPolymer conjugates of therapeutic peptides
WO2010033218A1 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of osteocalcin peptides
WO2010033204A2 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of c-peptides
EP2334334A1 (en)*2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of nesiritide peptides
EP2334337A1 (en)*2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of opioid growth factor peptides
EP2340045B1 (en)2008-09-192017-04-12Nektar TherapeuticsPolymer conjugates of protegrin peptides
WO2010056847A2 (en)2008-11-132010-05-20Taigen Biotechnology Co., Ltd.Lyophilization formulation
GB0823309D0 (en)*2008-12-192009-01-28Univ BathFunctionalising reagents and their uses
US20110318322A1 (en)2009-01-122011-12-29Nektar TherapeuticsConjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US8067201B2 (en)*2009-04-172011-11-29Bristol-Myers Squibb CompanyMethods for protein refolding
DE102010049607A1 (en)2009-10-262011-06-30Becker, Claus, Prof., 76470 Conjugates of nucleotides and methods for their use
CA2778678A1 (en)2009-10-302011-05-05Cns Therapeutics, Inc.Improved neurturin molecules
AR079344A1 (en)2009-12-222012-01-18Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
JO2976B1 (en)2009-12-222016-03-15ايلي ليلي اند كومبانيOxyntomodulin peptide analogue ‎
CN102161754B (en)*2010-02-132012-06-13华中科技大学同济医学院附属协和医院Functional modification method for branched polyethylene glycol (PEG) derivative
WO2011107591A1 (en)2010-03-052011-09-09RigshospitaletChimeric inhibitor molecules of complement activation
US8980253B2 (en)2010-04-262015-03-17Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
EP2563381B1 (en)2010-04-272017-08-09aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CA2797271C (en)2010-04-282021-05-25Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
JP5991963B2 (en)2010-04-292016-09-14エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of valyl tRNA synthetase
JP6008838B2 (en)2010-04-292016-10-19エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase
US9068177B2 (en)2010-04-292015-06-30Atyr Pharma, IncInnovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
EP2566495B1 (en)2010-05-032017-03-01aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
EP2566496B1 (en)2010-05-032018-02-28aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
EP2566515B1 (en)2010-05-032017-08-02aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CN102985103A (en)2010-05-042013-03-20Atyr医药公司Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2569331A1 (en)2010-05-102013-03-20Perseid Therapeutics LLCPolypeptide inhibitors of vla4
WO2011143482A2 (en)2010-05-142011-11-17Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011146410A2 (en)2010-05-172011-11-24Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
CN103119055A (en)2010-05-172013-05-22塞比克斯公司Pegylated C-Peptide
JP6023703B2 (en)2010-05-262016-11-09ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fibronectin based scaffold proteins with improved stability
CA2800281C (en)2010-06-012021-01-12Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CA2804416C (en)2010-07-122020-04-28Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
MX382876B (en)2010-07-302025-03-13Alcon Inc SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES.
AU2011293294B2 (en)2010-08-252016-03-24Pangu Biopharma LimitedInnovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
RU2441036C1 (en)*2010-09-302012-01-27Общество с ограниченной ответственностью Научно-производственное объединение "Перспектива" (ООО НПО "Перспектива")Method of producing activated polyethylene oxide
WO2012054822A1 (en)2010-10-222012-04-26Nektar TherapeuticsPharmacologically active polymer-glp-1 conjugates
CA3144697A1 (en)2010-11-122012-05-18Nektar TherapeuticsConjugates of an il-2 moiety and a polymer
AU2011332007C1 (en)2010-11-242017-03-02Lexicon Pharmaceuticals, Inc.Antibodies to Notum Pectinacetylesterase
US20140371258A1 (en)2010-12-172014-12-18Nektar TherapeuticsWater-Soluble Polymer Conjugates of Topotecan
US10736969B2 (en)2010-12-212020-08-11Nektar TherapeuticsMulti-arm polymeric prodrug conjugates of pemetrexed-based compounds
US10894087B2 (en)2010-12-222021-01-19Nektar TherapeuticsMulti-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en)2010-12-222013-12-12Nektar TherapeuticsMulti-arm polymeric prodrug conjugates of taxane-based compounds
US20140187488A1 (en)2011-05-172014-07-03Bristol-Myers Squibb CompanyMethods for maintaining pegylation of polypeptides
US20140088021A1 (en)2011-05-272014-03-27Nektar TherapeuticsWater-Soluble Polymer-Linked Binding Moiety and Drug Compounds
CN103687622A (en)2011-06-162014-03-26香港科技大学Multiple vinyl sulfone containing molecules
KR20140054009A (en)2011-07-012014-05-08바이엘 인텔렉쳐 프로퍼티 게엠베하Relaxin fusion polypeptides and uses thereof
WO2013020079A2 (en)2011-08-042013-02-07Nektar TherapeuticsConjugates of an il-11 moiety and a polymer
CN104053670A (en)2011-10-312014-09-17百时美施贵宝公司Fibronectin binding domains with reduced immunogenicity
CA2855770A1 (en)2011-11-172013-05-23Cebix AbPegylated c-peptide
WO2013123432A2 (en)2012-02-162013-08-22Atyr Pharma, Inc.Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2838577B1 (en)2012-04-022019-02-27SurModics, Inc.Hydrophilic polymeric coatings for medical articles with visualization moiety
WO2013177187A2 (en)2012-05-222013-11-28Massachusetts Institute Of TechnologySynergistic tumor treatment with extended-pk il-2 and therapeutic agents
HK1204557A1 (en)2012-05-312015-11-27Sorrento Therapeutics, Inc.Antigen binding proteins that bind pd-l1
CN109503714A (en)2012-06-212019-03-22索伦托治疗有限公司Antigen-binding proteins in conjunction with c-Met
EP2864358B1 (en)2012-06-222019-08-07Sorrento Therapeutics, Inc.Antigen binding proteins that bind ccr2
US9383357B2 (en)2012-12-072016-07-05Northwestern UniversityBiomarker for replicative senescence
WO2014120891A2 (en)2013-02-012014-08-07Bristol-Myers Squibb CompanyFibronectin based scaffold proteins
CA3175360C (en)2013-05-312024-05-28Sorrento Therapeutics, Inc.Antigen binding proteins that bind pd-1
CN104623637A (en)2013-11-072015-05-20健能隆医药技术(上海)有限公司Application of IL-22 dimer in preparation of intravenous injection drugs
EP3077008B1 (en)2013-12-062023-10-04Jie HanBioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
MA39711A (en)2014-04-032015-10-08Nektar TherapeuticsConjugates of an il-15 moiety and a polymer
US20170224777A1 (en)2014-08-122017-08-10Massachusetts Institute Of TechnologySynergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US10166273B2 (en)2014-08-122019-01-01The Board Of Trustees Of The Leland Stanford Junior UniversitySynergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
AU2015305894A1 (en)2014-08-222017-04-06Sorrento Therapeutics, Inc.Antigen binding proteins that bind CXCR3
SG11201701384XA (en)2014-10-142017-03-30Polytherics LtdProcess for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
BR112017005760A2 (en)*2014-10-242017-12-12Polytherics Ltd conjugates and conjugation reagents
GB201419108D0 (en)2014-10-272014-12-10Glythera LtdMaterials and methods relating to linkers for use in antibody drug conjugates
JP7407511B2 (en)2015-10-082024-01-04ネクター セラピューティクス Combination of IL-2Rβ selective agonist and long-acting IL-15 agonist
CN116333124A (en)2016-01-292023-06-27索伦托药业有限公司 Antigen-binding protein that binds to PD-L1
CN109328069B (en)2016-04-152023-09-01亿一生物医药开发(上海)有限公司Use of IL-22 in the treatment of necrotizing enterocolitis
CN109562167A (en)2016-08-092019-04-02伊莱利利公司Combination therapy
WO2018172503A2 (en)2017-03-242018-09-27Basf SeLiquid laundry detergent comprising modified saccharide or polysaccharide
CA3060410A1 (en)2017-05-152018-11-22Nektar TherapeuticsLong-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
US11485781B2 (en)2017-08-172022-11-01Massachusetts Institute Of TechnologyMultiple specificity binders of CXC chemokines
WO2019063958A1 (en)2017-09-272019-04-04The University Of YorkBioconjugation of polypeptides
MX2020005041A (en)2017-11-212020-10-12Univ Leland Stanford JuniorPartial agonists of interleukin-2.
KR102167755B1 (en)2018-05-232020-10-19주식회사 큐어바이오Fragmented GRS polypeptide, mutants thereof and use thereof
US12377294B2 (en)2018-08-282025-08-05Ambrx, Inc.Anti-CD3 antibody folate bioconjugates and their uses
MX2021006259A (en)2018-11-302021-09-30Eirgen Pharma LtdOxyntomodulin peptide analog formulations.
US11235032B2 (en)2019-01-232022-02-01Massachusetts Institute Of TechnologyCombination immunotherapy dosing regimen for immune checkpoint blockade
US11191709B2 (en)2019-04-262021-12-07The Procter & Gamble CompanyReduction of tooth staining derived from cationic antimicrobials
US11491205B2 (en)2020-01-142022-11-08Synthekine, Inc.Biased IL2 muteins methods and compositions
WO2021173889A1 (en)2020-02-262021-09-02Ambrx, Inc.Uses of anti-cd3 antibody folate bioconjugates
WO2024241086A1 (en)2023-05-242024-11-28Ambrx, Inc.Pegylated bovine interferon lambda and methods of use thereof

Citations (53)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3784524A (en)*1971-06-251974-01-08Grace W R & CoUrethane/thioether-containing polyene composition and the reaction product thereof
US4002531A (en)*1976-01-221977-01-11Pierce Chemical CompanyModifying enzymes with polyethylene glycol and product produced thereby
US4066581A (en)*1976-02-261978-01-03Behringwerke AktiengesellschaftProcess for producing a bond between polyvinylene glycol and a substance containing primary amino groups
US4066638A (en)*1973-10-171978-01-03Hoechst AktiengesellschaftWater-soluble fiber reactive phenyl-azo-naphthyl dyestuffs containing two sulfo groups in the phenyl moiety
US4101380A (en)*1975-06-121978-07-18Research Products Rehovot Ltd.Process for the cross-linking of proteins
US4134887A (en)*1973-10-171979-01-16Hoechst AktiengesellschaftPhenyl-azo-phenyl dyestuffs
US4179387A (en)*1974-03-121979-12-18Fuji Photo Film Co., Ltd.Process for producing magnetic FE oxide
US4179337A (en)*1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4228019A (en)*1978-06-191980-10-14Texaco Development Corp.Secondary recovery process
US4296097A (en)*1979-02-271981-10-20Lee Weng YSuppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor
US4356166A (en)*1978-12-081982-10-26University Of UtahTime-release chemical delivery system
US4424311A (en)*1981-07-011984-01-03Toray Industries, IncorporatedAntithrombogenic biomedical material
US4430260A (en)*1979-02-271984-02-07Lee Weng YPenicillin-polyvinyl alcohol conjugate and process of preparation
US4473693A (en)*1978-08-041984-09-25Stewart Walter WAminonaphthalimide dyes for intracellular labelling
US4559179A (en)*1983-04-121985-12-17Daikan Kogyo Co., Ltd.Fluorine-containing vinyl compound
US4616644A (en)*1985-06-141986-10-14Johnson & Johnson Products, Inc.Hemostatic adhesive bandage
WO1987000056A1 (en)*1985-06-261987-01-15Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US4670417A (en)*1985-06-191987-06-02Ajinomoto Co., Inc.Hemoglobin combined with a poly(alkylene oxide)
US4677027A (en)*1984-10-191987-06-30Exploaterings Ab T.B.F.Polymer coated particles having immobilized metal ions on the surfaces thereof
US4696980A (en)*1984-05-171987-09-29Jerker PorathSulfone activated thioether adsorbents for the separation of proteins and the like
EP0247860A2 (en)*1986-05-291987-12-02Cetus Oncology CorporationTumor necrosis factor formulation and its preparation
US4766106A (en)*1985-06-261988-08-23Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en)*1986-06-261988-12-13Takeda Chemical Industries, Ltd.Chemically modified protein with polyethyleneglycol
US4845024A (en)*1986-08-231989-07-04Agfa Gevaert AktiengessellschaftHardeners for proteins, a binder layer hardened therewith and a photographic recording material containing such a layer
US4871785A (en)*1986-08-131989-10-03Michael FroixClouding-resistant contact lens compositions
US4883864A (en)*1985-09-061989-11-28Minnesota Mining And Manufacturing CompanyModified collagen compound and method of preparation
US4902502A (en)*1989-01-231990-02-20Cetus CorporationPreparation of a polymer/interleukin-2 conjugate
US4917888A (en)*1985-06-261990-04-17Cetus CorporationSolubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
WO1990004606A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineA process for fractionating polyethylene glycol (peg)-protein adducts and an adduct of peg and granulocyte-macrophage colony stimulating factor
WO1990004650A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineA purification process for covalently bound dna/protein complexes
WO1990004384A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineLiposomes
US4931544A (en)*1986-09-041990-06-05Cetus CorporationSuccinylated interleukin-2 for pharmaceutical compositions
US4931579A (en)*1986-10-101990-06-05Miles Inc.Indicators for the detection of thiol groups
US4965112A (en)*1988-03-081990-10-23Stichting Voor De Technische WetenschappenMethod for applying a blood-compatible coating to polyether-urethane moulded articles and the polymether-urethane moulded articles coated in this way
US4973493A (en)*1982-09-291990-11-27Bio-Metric Systems, Inc.Method of improving the biocompatibility of solid surfaces
WO1990015628A1 (en)*1989-06-141990-12-27Cetus CorporationPolymer/antibiotic conjugate
US4983494A (en)*1985-10-161991-01-08Fuji Photo Film Co., Ltd.Image forming process including heating step
WO1991007190A1 (en)*1989-11-221991-05-30Enzon, Inc.Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5080891A (en)*1987-08-031992-01-14Ddi Pharmaceuticals, Inc.Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5089261A (en)*1989-01-231992-02-18Cetus CorporationPreparation of a polymer/interleukin-2 conjugate
WO1992004384A1 (en)*1990-08-311992-03-19Regents Of The University Of MinnesotaPolyethylene glycol derivatives for solid-phase applications
WO1992007006A1 (en)*1990-10-221992-04-30Berol Nobel AbA solid surface coated with a hydrophilic outer layer with covalently bonded biopolymers, a method of making such a surface, and a conjugate therefor
WO1992006678A1 (en)*1990-10-151992-04-30Board Of Regents, The University Of Texas SystemBiocompatible microcapsules
US5122614A (en)*1989-04-191992-06-16Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
WO1992013095A1 (en)*1991-01-181992-08-06Synergen, Inc.Methods for treating tumor necrosis factor mediated diseases
WO1992016555A1 (en)*1991-03-181992-10-01Enzon, Inc.Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1992016292A1 (en)*1991-03-221992-10-01Kem-En-Tec A/SAdsorption matrices
WO1992016221A1 (en)*1991-03-151992-10-01Synergen, Inc.Pegylation of polypeptides
US5153265A (en)*1988-01-201992-10-06Cetus CorporationConjugation of polymer to colony stimulating factor-1
US5162430A (en)*1988-11-211992-11-10Collagen CorporationCollagen-polymer conjugates
US5171264A (en)*1990-02-281992-12-15Massachusetts Institute Of TechnologyImmobilized polyethylene oxide star molecules for bioapplications
WO1993001498A1 (en)*1991-07-041993-01-21Immunodex K/SWater-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
EP0622394A1 (en)*1993-04-301994-11-02S.A. Laboratoires S.M.B.Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE2850058A1 (en)*1978-11-181980-05-29Bayer Ag POLYAETHER DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
US4241199A (en)*1979-09-181980-12-23Union Carbide CorporationNovel polyester diols
US4280979A (en)*1979-09-181981-07-28Union Carbide CorporationCopolymers, compositions, and articles, and methods for making same
DK130991D0 (en)*1991-07-041991-07-04Immunodex K S POLYMER CONJUGATES
US5414135A (en)1991-12-301995-05-09Sterling Winthrop Inc.Vinyl sulfone coupling of polyoxyalkylenes to proteins

Patent Citations (53)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3784524A (en)*1971-06-251974-01-08Grace W R & CoUrethane/thioether-containing polyene composition and the reaction product thereof
US4179337A (en)*1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4066638A (en)*1973-10-171978-01-03Hoechst AktiengesellschaftWater-soluble fiber reactive phenyl-azo-naphthyl dyestuffs containing two sulfo groups in the phenyl moiety
US4134887A (en)*1973-10-171979-01-16Hoechst AktiengesellschaftPhenyl-azo-phenyl dyestuffs
US4179387A (en)*1974-03-121979-12-18Fuji Photo Film Co., Ltd.Process for producing magnetic FE oxide
US4101380A (en)*1975-06-121978-07-18Research Products Rehovot Ltd.Process for the cross-linking of proteins
US4002531A (en)*1976-01-221977-01-11Pierce Chemical CompanyModifying enzymes with polyethylene glycol and product produced thereby
US4066581A (en)*1976-02-261978-01-03Behringwerke AktiengesellschaftProcess for producing a bond between polyvinylene glycol and a substance containing primary amino groups
US4228019A (en)*1978-06-191980-10-14Texaco Development Corp.Secondary recovery process
US4473693A (en)*1978-08-041984-09-25Stewart Walter WAminonaphthalimide dyes for intracellular labelling
US4356166A (en)*1978-12-081982-10-26University Of UtahTime-release chemical delivery system
US4430260A (en)*1979-02-271984-02-07Lee Weng YPenicillin-polyvinyl alcohol conjugate and process of preparation
US4296097A (en)*1979-02-271981-10-20Lee Weng YSuppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor
US4424311A (en)*1981-07-011984-01-03Toray Industries, IncorporatedAntithrombogenic biomedical material
US4973493A (en)*1982-09-291990-11-27Bio-Metric Systems, Inc.Method of improving the biocompatibility of solid surfaces
US4559179A (en)*1983-04-121985-12-17Daikan Kogyo Co., Ltd.Fluorine-containing vinyl compound
US4696980A (en)*1984-05-171987-09-29Jerker PorathSulfone activated thioether adsorbents for the separation of proteins and the like
US4677027A (en)*1984-10-191987-06-30Exploaterings Ab T.B.F.Polymer coated particles having immobilized metal ions on the surfaces thereof
US4616644A (en)*1985-06-141986-10-14Johnson & Johnson Products, Inc.Hemostatic adhesive bandage
US4670417A (en)*1985-06-191987-06-02Ajinomoto Co., Inc.Hemoglobin combined with a poly(alkylene oxide)
WO1987000056A1 (en)*1985-06-261987-01-15Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en)*1985-06-261988-08-23Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)*1985-06-261990-04-17Cetus CorporationSolubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4883864A (en)*1985-09-061989-11-28Minnesota Mining And Manufacturing CompanyModified collagen compound and method of preparation
US4983494A (en)*1985-10-161991-01-08Fuji Photo Film Co., Ltd.Image forming process including heating step
EP0247860A2 (en)*1986-05-291987-12-02Cetus Oncology CorporationTumor necrosis factor formulation and its preparation
US4791192A (en)*1986-06-261988-12-13Takeda Chemical Industries, Ltd.Chemically modified protein with polyethyleneglycol
US4871785A (en)*1986-08-131989-10-03Michael FroixClouding-resistant contact lens compositions
US4845024A (en)*1986-08-231989-07-04Agfa Gevaert AktiengessellschaftHardeners for proteins, a binder layer hardened therewith and a photographic recording material containing such a layer
US4931544A (en)*1986-09-041990-06-05Cetus CorporationSuccinylated interleukin-2 for pharmaceutical compositions
US4931579A (en)*1986-10-101990-06-05Miles Inc.Indicators for the detection of thiol groups
US5080891A (en)*1987-08-031992-01-14Ddi Pharmaceuticals, Inc.Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5153265A (en)*1988-01-201992-10-06Cetus CorporationConjugation of polymer to colony stimulating factor-1
US4965112A (en)*1988-03-081990-10-23Stichting Voor De Technische WetenschappenMethod for applying a blood-compatible coating to polyether-urethane moulded articles and the polymether-urethane moulded articles coated in this way
WO1990004384A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineLiposomes
WO1990004650A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineA purification process for covalently bound dna/protein complexes
WO1990004606A1 (en)*1988-10-201990-05-03Royal Free Hospital School Of MedicineA process for fractionating polyethylene glycol (peg)-protein adducts and an adduct of peg and granulocyte-macrophage colony stimulating factor
US5162430A (en)*1988-11-211992-11-10Collagen CorporationCollagen-polymer conjugates
US4902502A (en)*1989-01-231990-02-20Cetus CorporationPreparation of a polymer/interleukin-2 conjugate
US5089261A (en)*1989-01-231992-02-18Cetus CorporationPreparation of a polymer/interleukin-2 conjugate
US5122614A (en)*1989-04-191992-06-16Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990015628A1 (en)*1989-06-141990-12-27Cetus CorporationPolymer/antibiotic conjugate
WO1991007190A1 (en)*1989-11-221991-05-30Enzon, Inc.Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5171264A (en)*1990-02-281992-12-15Massachusetts Institute Of TechnologyImmobilized polyethylene oxide star molecules for bioapplications
WO1992004384A1 (en)*1990-08-311992-03-19Regents Of The University Of MinnesotaPolyethylene glycol derivatives for solid-phase applications
WO1992006678A1 (en)*1990-10-151992-04-30Board Of Regents, The University Of Texas SystemBiocompatible microcapsules
WO1992007006A1 (en)*1990-10-221992-04-30Berol Nobel AbA solid surface coated with a hydrophilic outer layer with covalently bonded biopolymers, a method of making such a surface, and a conjugate therefor
WO1992013095A1 (en)*1991-01-181992-08-06Synergen, Inc.Methods for treating tumor necrosis factor mediated diseases
WO1992016221A1 (en)*1991-03-151992-10-01Synergen, Inc.Pegylation of polypeptides
WO1992016555A1 (en)*1991-03-181992-10-01Enzon, Inc.Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1992016292A1 (en)*1991-03-221992-10-01Kem-En-Tec A/SAdsorption matrices
WO1993001498A1 (en)*1991-07-041993-01-21Immunodex K/SWater-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
EP0622394A1 (en)*1993-04-301994-11-02S.A. Laboratoires S.M.B.Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CA95: 33396 vol. 95 (1981) Minamizono et al. DT3002724.*
Woghiren, et al., Protected Thiol Polyethylene Glycol: A New Activated Polymer For Reversible Protein Modification, Bioconjugate Chem. 1993, vol. 4, No. 5, pp. 314 318.*
Woghiren, et al., Protected Thiol-Polyethylene Glycol: A New Activated Polymer For Reversible Protein Modification, Bioconjugate Chem. 1993, vol. 4, No. 5, pp. 314-318.
Yoshinaga et al., Effects of Coupling Chemistry on the Activity of Poly(ethylene glycol) Modifified Alkaline Phosphatase, Journal of Bioactive and Compatible Polymers, Jan., 1989, vol. 4, pp. 17 24.*
Yoshinaga et al., Effects of Coupling Chemistry on the Activity of Poly(ethylene glycol)-Modifified Alkaline Phosphatase, Journal of Bioactive and Compatible Polymers, Jan., 1989, vol. 4, pp. 17-24.

Cited By (651)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6143866A (en)*1989-07-182000-11-07Amgen, Inc.Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US20030190304A1 (en)*1990-04-062003-10-09Amgen Inc.Pegylation reagents and compounds formed therewith
US6552170B1 (en)*1990-04-062003-04-22Amgen Inc.PEGylation reagents and compounds formed therewith
US8663629B2 (en)1994-01-112014-03-04Dyax Corp.Kallikrein-binding “kunitz domain” proteins and analogues thereof
US8137989B2 (en)1994-03-182012-03-20Cytimmune Sciences, Inc.Method for delivering a cytokine using a colloidal metal
EP0758906A1 (en)*1994-06-141997-02-26Tadahiko KohnoPegylation reagents and compounds formed therewith
US5672662A (en)*1995-07-071997-09-30Shearwater Polymers, Inc.Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6989147B2 (en)1996-07-092006-01-24Amgen Inc.Truncated soluble tumor necrosis factor type-I and type-II receptors
US7732587B2 (en)1996-07-092010-06-08Amgen Inc.Nucleic acids encoding truncated soluble tumor necrosis factor
US20050250696A1 (en)*1996-07-092005-11-10Fisher Eric FTruncated soluble tumor necrosis factor type-I and type-II receptors
US7605232B2 (en)1996-09-232009-10-20Incept LlcHydrogels for protein concentration
US20100069613A1 (en)*1996-09-232010-03-18Incept LlcImplantable materials and compositions
US20020114775A1 (en)*1996-09-232002-08-22Incept LlcCrosslinking agents and methods of use
US6887974B2 (en)1996-09-232005-05-03Incept LlcCrosslinking agents and methods of use
US7057019B2 (en)1996-09-232006-06-06Incept LlcCrosslinked albumin hydrogels
US8557535B2 (en)1996-09-232013-10-15Incept LlcMethods for preparation of platelet rich plasma
US20070197776A1 (en)*1996-09-232007-08-23Incept LlcHydrogels for protein concentration
US20040002456A1 (en)*1996-09-232004-01-01Incept LlcMethods and devices for preparing protein concentrates
US8003705B2 (en)1996-09-232011-08-23Incept LlcBiocompatible hydrogels made with small molecule precursors
US7211651B2 (en)1996-09-232007-05-01Incept LlcProteinaceous gels having visualization agents and methods of use thereof
US20030077272A1 (en)*1996-09-232003-04-24Incept LlcProteinaceous gels having visualization agents and methods of use thereof
US20080260802A1 (en)*1996-09-232008-10-23Sawhney Amarpreet SBiocompatible hydrogels made with small molecule precursors
US6072040A (en)*1996-10-152000-06-06Medical Analysis Systems, Inc.Stabilized conjugates of uncomplexed subunits of multimeric proteins
US6491923B1 (en)1996-10-152002-12-10Ivan E. ModrovichStabilized conjugates of uncomplexed subunits of multimeric proteins
US6306820B1 (en)1996-12-062001-10-23Amgen Inc.Combination therapy using a TNF binding protein for treating TNF-mediated diseases
WO1998051336A1 (en)*1997-05-151998-11-19Theratech, Inc.Targeted delivery to t lymphocytes
US6284246B1 (en)1997-07-302001-09-04The Procter & Gamble Co.Modified polypeptides with high activity and reduced allergenicity
US6693083B2 (en)1997-08-052004-02-17Watson Pharmaceuticals, Inc.Conjugates targeted to the interleukin-2 receptor
US6129928A (en)*1997-09-052000-10-10Icet, Inc.Biomimetic calcium phosphate implant coatings and methods for making the same
US7790167B2 (en)1997-11-102010-09-07Cyt Immune Sciences, Inc.Methods and compositions for enhancing immune response and for the production of in vitro Mabs
US20030180252A1 (en)*1997-11-102003-09-25Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro Mabs
US6066673A (en)*1998-03-122000-05-23The Procter & Gamble CompanyEnzyme inhibitors
US6569663B1 (en)1998-03-262003-05-27The Procter & Gamble CompanySerine protease variants having amino acid substitutions
US6495136B1 (en)1998-03-262002-12-17The Procter & Gamble CompanyProteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en)1998-03-262005-06-21The Procter & Gamble CompanySerine protease variants having amino acid deletions and substitutions
US20040033264A1 (en)*1998-08-142004-02-19Incept LlcComposite hydrogel drug delivery systems
US6632457B1 (en)1998-08-142003-10-14Incept LlcComposite hydrogel drug delivery systems
US20080279944A1 (en)*1998-08-142008-11-13Incept LlcComposite hydrogel drug delivery systems
US9254267B2 (en)1998-08-142016-02-09Incept, LlcComposite hydrogel drug delivery systems
US7413752B2 (en)1998-08-142008-08-19Incept LlcComposite hydrogel drug delivery systems
US20080181944A1 (en)*1998-09-082008-07-31Alza CorporationDosage Form Comprising Therapeutic Formulation
US20090130204A1 (en)*1998-09-082009-05-21Encinal Pharmaceutical Investment Inc.Dosage Form Comprising Therapeutic Formulation
US20030157163A1 (en)*1998-09-082003-08-21Liang-Chang DongDosage form comprising therapeutic formulation
US20100159002A1 (en)*1998-09-082010-06-24Liang-Chang DongDosage form comprising therapeutic formulation
US6410017B1 (en)1998-09-222002-06-25The Procter & Gamble CompanyPersonal care compositions containing active proteins tethered to a water insoluble substrate
US20040087778A1 (en)*1998-10-232004-05-06Amgen Inc.Modified peptides as therapeutic agents
US7186810B2 (en)1998-10-232007-03-06Amgen Inc.Modified peptides as therapeutic agents
US20070160572A1 (en)*1998-11-102007-07-12Lawrence TamarkinColloidal metal compositions and methods
US20040023842A1 (en)*1998-12-042004-02-05InceptBiocompatible crosslinked polymers
US8535705B2 (en)1998-12-042013-09-17Incept, LlcBiocompatible polymers and hydrogels and methods of use
US20030162841A1 (en)*1998-12-042003-08-28InceptBiocompatible crosslinked polymers
US7670605B2 (en)1999-02-012010-03-02Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7744912B1 (en)1999-02-012010-06-29Eidgenossische Technische Hochschule ZurichBiomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US20060127352A1 (en)*1999-02-012006-06-15Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US20090098083A1 (en)*1999-02-012009-04-16Hubbell Jeffrey AConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7413739B2 (en)1999-02-012008-08-19Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2000078285A1 (en)*1999-06-182000-12-28University Of Medicine And Dentistry Of New JerseyControlled release of therapeutics by in-situ entrapment by matrix cross-linking
US6586223B1 (en)1999-07-222003-07-01The Procter & Gamble CompanySubtilisin protease variants having amino acid substitutions in defined epitope regions
US6586224B1 (en)1999-07-222003-07-01The Procter & Gamble CompanySubtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6566115B1 (en)1999-07-222003-05-20The Procter & Gamble CompanyProtease conjugates having sterically protected clip sites
US6946128B1 (en)1999-07-222005-09-20The Procter & Gamble CompanyProtease conjugates having sterically protected epitope regions
US6303119B1 (en)1999-09-222001-10-16The Procter & Gamble CompanyPersonal care compositions containing subtilisin enzymes bound to water insoluble substrates
US6818435B2 (en)2000-05-152004-11-16Tecan Trading AgMicrofluidics devices and methods for performing cell based assays
US20030220245A1 (en)*2000-06-022003-11-27Hubbell Jeffrey AConjugate addition reactions for the controlled delivery of pharmaceutical active compounds
US7291673B2 (en)2000-06-022007-11-06Eidgenossiche Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US20050089970A1 (en)*2000-07-122005-04-28Bradburne James A.Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
US20060233747A1 (en)*2000-09-082006-10-19Amylin Pharmaceuticals, Inc.Polymer-modified synthetic proteins
US7118737B2 (en)2000-09-082006-10-10Amylin Pharmaceuticals, Inc.Polymer-modified synthetic proteins
US20030191291A1 (en)*2000-09-082003-10-09Kochendoerfer Gerd G.Synthetic erythropoiesis stimulating proteins
US7132475B2 (en)2000-10-192006-11-07Ecole Polytechnique Federale De LausanneBlock copolymers for multifunctional self-assembled systems
US20030059906A1 (en)*2000-10-192003-03-27Hubbell Jeffrey A.Block copolymers for multifunctional self-assembled systems
US20040185103A1 (en)*2000-10-312004-09-23Danny LewisMethods and compositions for enhanced delivery of bioactive molecules
EP2316490A2 (en)2000-10-312011-05-04PR Pharmaceuticals, Inc.Methods and compositions for enhanced delivery of bioactive molecules
US6706289B2 (en)2000-10-312004-03-16Pr Pharmaceuticals, Inc.Methods and compositions for enhanced delivery of bioactive molecules
US20030044468A1 (en)*2001-03-202003-03-06Francesco CellesiTwo-phase processing of thermosensitive polymers for use as biomaterials
US6538104B2 (en)2001-04-272003-03-25Medical Analysis Systems, Inc.Stabilization of cardiac troponin I subunits and complexes
US6989436B2 (en)2001-04-272006-01-24Medical Analysis Systems, Inc.Stabilization of cardiac troponin I subunits and complexes
US20030176638A1 (en)*2001-04-272003-09-18Medical Analysis Systems, Inc.Stabilization of cardiac troponin I subunits and complexes
US20070231408A1 (en)*2001-04-302007-10-04Lawrence TamarkinColloidal metal compositions and methods
US8785202B2 (en)2001-04-302014-07-22Cytimmune Sciences, Inc.Colloidal metal compositions and methods
USRE42524E1 (en)2001-04-302011-07-05Cytimmune Sciences, Inc.Colloidal metal compositions and methods
US20100143298A1 (en)*2001-04-302010-06-10Lawrence TamarkinColloidal metal compositions and methods
US20040077835A1 (en)*2001-07-122004-04-22Robin OffordChemokine receptor modulators, production and use
WO2003018665A1 (en)*2001-08-222003-03-06Bioartificial Gel Technologies Inc.Process for the preparation of activated polyethylene glycols
US7125558B2 (en)2001-08-222006-10-24Bioartificial Gel Technologies Inc,Process for the preparation of activated polyethylene glycols
EP2305313A2 (en)2001-10-102011-04-06BioGeneriX AGRemodelling and glycoconjugation of interferon-alpha (IFNa)
EP2279755A2 (en)2001-10-102011-02-02BioGeneriX AGRemodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
US8716239B2 (en)2001-10-102014-05-06Novo Nordisk A/SGranulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF
EP2305314A2 (en)2001-10-102011-04-06BioGeneriX AGRemodelling and glycoconjugation of antibodies
US8716240B2 (en)2001-10-102014-05-06Novo Nordisk A/SErythropoietin: remodeling and glycoconjugation of erythropoietin
EP2305311A2 (en)2001-10-102011-04-06BioGeneriX AGGlycoconjugation of peptides
EP2042196A2 (en)2001-10-102009-04-01Neose Technologies, Inc.Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2305312A2 (en)2001-10-102011-04-06BioGeneriX AGRemodelling and glycoconjugation of follicle-stimulating hormone (FSH)
EP2298354A2 (en)2001-10-102011-03-23BioGeneriX AGRemodelling and glycoconjugation of interferon-beta
EP2080525A1 (en)2001-10-102009-07-22BioGeneriX AGRemodeling and Glycoconjugation of Peptides
US7795210B2 (en)2001-10-102010-09-14Novo Nordisk A/SProtein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en)2001-10-102011-08-30Novo Nordisk A/SFactor VII: remodeling and glycoconjugation of Factor VII
US8076292B2 (en)2001-10-102011-12-13Novo Nordisk A/SFactor VIII: remodeling and glycoconjugation of factor VIII
EP2322229A2 (en)2001-10-102011-05-18Novo Nordisk A/SRemodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2279754A2 (en)2001-10-102011-02-02BioGeneriX AGRemodelling and glycoconjugation of human growth hormone (hGH)
EP2279753A2 (en)2001-10-102011-02-02Novo Nordisk A/SRemodeling and glycoconjugation of peptides
US20030179692A1 (en)*2002-03-192003-09-25Yoshitaka OhotomoStorage medium
US20100034769A1 (en)*2002-03-222010-02-11Kuros Biosurgery, AGCompositions for tissue augmentation
US8282912B2 (en)2002-03-222012-10-09Kuros Biosurgery, AGCompositions for tissue augmentation
US20110086801A1 (en)*2002-06-072011-04-14Dyax Corp.Prevention and reduction of blood loss
US8710007B2 (en)2002-06-072014-04-29Dyax Corp.Prevention and reduction of blood loss
US10245307B2 (en)2002-06-072019-04-02Dyax Corp.Prevention and reduction of blood loss
US9114144B2 (en)2002-06-072015-08-25Dyax Corp.Kallikrein-inhibitor therapies
US9480733B2 (en)2002-06-072016-11-01Dyax Corp.Prevention and reduction of blood loss
US11344610B2 (en)2002-06-072022-05-31Takeda Pharmaceutical Company LimitedPrevention and reduction of blood loss
US8053410B2 (en)2002-06-212011-11-08Novo Nordisk Health Care A/GPegylated factor VII glycoforms
US20040136956A1 (en)*2002-09-052004-07-15Barker Nicholas P.Asialo-interferons and the treatment of liver cancer
US20040136955A1 (en)*2002-09-052004-07-15Barker Nicholas PModified asialo-interferons and uses thereof
US20090264600A1 (en)*2002-09-092009-10-22Nektar Therapeutics Al, CorporationMethod for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid
US9045494B2 (en)2002-09-092015-06-02Nektar TherapeuticsOrthoester compound
US8435504B2 (en)2002-09-092013-05-07Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US20050036978A1 (en)*2002-09-092005-02-17Antoni KozlowskiMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US7569214B2 (en)2002-09-092009-08-04Nektar Therapeutics Al, CorporationMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US8182801B2 (en)2002-09-092012-05-22Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US8784791B2 (en)2002-09-092014-07-22Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester
US20040136952A1 (en)*2002-12-262004-07-15Mountain View Pharmaceuticals, Inc.Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US20040126361A1 (en)*2002-12-262004-07-01Mountain View Pharmaceuticals, Inc.Polymer conjugates of interferon-beta with enhanced biological potency
US20080058246A1 (en)*2002-12-262008-03-06Mountain View Pharmaceuticals, Inc.Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US9125880B2 (en)2002-12-262015-09-08Mountain View Pharmaceuticals, Inc.Polymer conjugates of interferon-beta with enhanced biological potency
US8034900B2 (en)2002-12-302011-10-11Amylin Pharmaceuticals, Inc.Water-soluble thioester and selenoester compounds and methods for making and using the same
WO2004061094A1 (en)2002-12-302004-07-22Gryphon Therapeutics, Inc.Water-soluble thioester and selenoester compounds and methods for making and using the same
US20060173159A1 (en)*2002-12-302006-08-03Miranda Leslie PWater-soluble thioester and selenoester compounds and methods for making and using the same
AU2004204136B2 (en)*2003-01-062008-10-09Nektar TherapeuticsThiol-selective water-soluble polmer derivatives
US8722032B2 (en)2003-01-062014-05-13Nektar TherapeuticsThiol-selective water-soluble polymer derivatives
WO2004063250A1 (en)*2003-01-062004-07-29Nektar Therapeutics Al, CorporationThiol-selective water-soluble polmer derivatives
US9040658B2 (en)2003-01-062015-05-26Nektar TherapeuticsThiol-selective water-soluble polymer derivatives
US20050014903A1 (en)*2003-01-062005-01-20Antoni KozlowskiThiol selective water soluble polymer derivatives
US20060014248A1 (en)*2003-01-062006-01-19Xencor, Inc.TNF super family members with altered immunogenicity
US20050221443A1 (en)*2003-01-062005-10-06Xencor, Inc.Tumor necrosis factor super family agonists
US20050048626A1 (en)*2003-01-062005-03-03Xencor, Inc.BAFF variants and methods thereof
US9333267B2 (en)2003-01-062016-05-10Nektar TherapeuticsThiol-selective water-soluble polymer derivatives
US20110034643A1 (en)*2003-01-062011-02-10Nektar TherapeuticsThiol-Selective Water-Soluble Polymer Derivatives
US7910661B2 (en)*2003-01-062011-03-22Nektar TherapeuticsThiol-selective water-soluble polymer derivatives
US7553930B2 (en)2003-01-062009-06-30Xencor, Inc.BAFF variants and methods thereof
US8202517B2 (en)2003-03-052012-06-19Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090181013A1 (en)*2003-03-052009-07-16Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20110008309A1 (en)*2003-03-052011-01-13Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050260186A1 (en)*2003-03-052005-11-24Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7767429B2 (en)2003-03-052010-08-03Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431124B2 (en)2003-03-052013-04-30Halozyme, Inc.Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US8450470B2 (en)2003-03-052013-05-28Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090253175A1 (en)*2003-03-052009-10-08Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090181032A1 (en)*2003-03-052009-07-16Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en)*2003-03-052006-05-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8105586B2 (en)2003-03-052012-01-31Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en)*2003-03-052009-05-14DelfmemsSoluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20090214505A1 (en)*2003-03-052009-08-27Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en)2003-03-052011-01-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20040268425A1 (en)*2003-03-052004-12-30Deliatroph Pharmaceuticals, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431380B2 (en)2003-03-052013-04-30Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050130892A1 (en)*2003-03-072005-06-16Xencor, Inc.BAFF variants and methods thereof
US7803777B2 (en)2003-03-142010-09-28Biogenerix AgBranched water-soluble polymers and their conjugates
US8247381B2 (en)2003-03-142012-08-21Biogenerix AgBranched water-soluble polymers and their conjugates
US20080113410A1 (en)*2003-03-312008-05-15Xencor, Inc.Method for Rational Pegylation of Proteins
US7587286B2 (en)2003-03-312009-09-08Xencor, Inc.Methods for rational pegylation of proteins
US7610156B2 (en)2003-03-312009-10-27Xencor, Inc.Methods for rational pegylation of proteins
US20040249576A1 (en)*2003-03-312004-12-09XencorMethods for rational pegylation of proteins
US20050114037A1 (en)*2003-03-312005-05-26Xencor, Inc.Methods for rational pegylation of proteins
US7642340B2 (en)2003-03-312010-01-05Xencor, Inc.PEGylated TNF-α variant proteins
EP2055189A1 (en)2003-04-092009-05-06Neose Technologies, Inc.Glycopegylation methods and proteins/peptides produced by the methods
EP2338333A2 (en)2003-04-092011-06-29BioGeneriX AGGlycopegylation methods and proteins/peptides produced by the methods
US8853161B2 (en)2003-04-092014-10-07Novo Nordisk A/SGlycopegylation methods and proteins/peptides produced by the methods
US8063015B2 (en)2003-04-092011-11-22Novo Nordisk A/SGlycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en)2003-04-092014-07-29Novo Nordisk A/SGlycopegylated factor IX
US9789196B2 (en)2003-04-112017-10-17Antriabio, Inc.Site-specific insulin-polymer conjugates
EP2599502A2 (en)2003-04-112013-06-05PR Pharmaceuticals Inc.Method for preparation of site-specific protein conjugates
US9040664B2 (en)2003-04-112015-05-26Antriabio, Inc.Materials and methods for preparing protein-polymer conjugates
US7932364B2 (en)2003-05-092011-04-26Novo Nordisk A/SCompositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en)2003-07-252015-04-14Novo Nordisk A/SAntibody toxin conjugates
US20070041959A1 (en)*2003-08-292007-02-22Dyax Corp., A Delaware CorporationPoly-pegylated protease inhibitors
US7550427B2 (en)2003-08-292009-06-23Dyax Corp.Poly-pegylated protease inhibitors
US20050089515A1 (en)*2003-08-292005-04-28Dyax Corp.Poly-pegylated protease inhibitors
EP2327723A2 (en)2003-10-102011-06-01Xencor, Inc.Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7842661B2 (en)2003-11-242010-11-30Novo Nordisk A/SGlycopegylated erythropoietin formulations
US8916360B2 (en)2003-11-242014-12-23Novo Nordisk A/SGlycopegylated erythropoietin
US8633157B2 (en)2003-11-242014-01-21Novo Nordisk A/SGlycopegylated erythropoietin
US7951614B2 (en)2003-12-022011-05-31Cytimmune Sciences, Inc.Methods and compositions for the production of monoclonal antibodies
US8632770B2 (en)2003-12-032014-01-21Novo Nordisk A/SGlycopegylated factor IX
US20100330060A1 (en)*2003-12-032010-12-30Novo Nordisk A/SGlycopegylated factor ix
US7956032B2 (en)2003-12-032011-06-07Novo Nordisk A/SGlycopegylated granulocyte colony stimulating factor
US20050250678A1 (en)*2004-01-082005-11-10Neose Technologies, Inc.O-linked glycosylation of peptides
US7338933B2 (en)2004-01-082008-03-04Neose Technologies, Inc.O-linked glycosylation of peptides
US8361961B2 (en)2004-01-082013-01-29Biogenerix AgO-linked glycosylation of peptides
US20050175584A1 (en)*2004-01-282005-08-11Paciotti Giulio F.Functionalized colloidal metal compositions and methods
US8906676B2 (en)2004-02-022014-12-09Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US8097702B2 (en)2004-02-022012-01-17Ambrx, Inc.Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
EP2327724A2 (en)2004-02-022011-06-01Ambrx, Inc.Modified human growth hormone polypeptides and their uses
US20080207877A1 (en)*2004-02-022008-08-28Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US20080146781A1 (en)*2004-02-022008-06-19Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US8778880B2 (en)2004-02-022014-07-15Ambrx, Inc.Human growth hormone modified at position 35
US8232371B2 (en)2004-02-022012-07-31Ambrx, Inc.Modified human interferon polypeptides and their uses
US9260472B2 (en)2004-02-022016-02-16Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US8907064B2 (en)2004-02-022014-12-09Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US20080097083A1 (en)*2004-02-022008-04-24Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US8119603B2 (en)2004-02-022012-02-21Ambrx, Inc.Modified human interferon polypeptides and their uses
US20080114154A1 (en)*2004-02-022008-05-15Ambrx, Inc.Modified Human Interferon Polypeptides and Their Uses
US9211315B2 (en)2004-03-052015-12-15Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7351787B2 (en)2004-03-052008-04-01Bioartificial Gel Technologies, Inc.Process for the preparation of activated polyethylene glycols
US20080139854A1 (en)*2004-03-052008-06-12Marie-Pierre FaureProcess for the preparation of activated polyethylene glycols
US8257699B2 (en)2004-03-052012-09-04Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050228187A1 (en)*2004-03-052005-10-13Marie-Pierre FaureProcess for the preparation of activated polyethylene glycols
US8580252B2 (en)2004-03-052013-11-12Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7662908B2 (en)2004-03-052010-02-16Rba Pharma Inc.Process for the preparation of activated polythylene glycols
US10016491B2 (en)2004-03-052018-07-10Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050261232A1 (en)*2004-04-132005-11-24Quintessence Biosciences, Inc.Non-natural ribonuclease conjugates as cytotoxic agents
US8697065B2 (en)2004-04-132014-04-15Quintessence Biosciences, Inc.Non-natural ribonuclease conjugates as cytotoxic agents
US9393319B2 (en)2004-04-132016-07-19Quintessence Biosciences, Inc.Non-natural ribonuclease conjugates as cytotoxic agents
US8470315B2 (en)2004-04-132013-06-25Quintessence Biosciences, Inc.Non-natural ribonuclease conjugates as cytotoxic agents
US20080085277A1 (en)*2004-06-182008-04-10Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US7632924B2 (en)2004-06-182009-12-15Ambrx, Inc.Antigen-binding polypeptides and their uses
US20060153860A1 (en)*2004-06-182006-07-13Ambrx, Inc.Novel antigen-binding polypeptides and their uses
WO2006009901A2 (en)2004-06-182006-01-26Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US9175083B2 (en)2004-06-182015-11-03Ambrx, Inc.Antigen-binding polypeptides and their uses
US8791066B2 (en)2004-07-132014-07-29Novo Nordisk A/SBranched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
US7638299B2 (en)2004-07-212009-12-29Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20100048871A1 (en)*2004-07-212010-02-25Ambrx, Inc.Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
US20060019347A1 (en)*2004-07-212006-01-26Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8268967B2 (en)2004-09-102012-09-18Novo Nordisk A/SGlycopegylated interferon α
US8716225B2 (en)2004-09-272014-05-06Dyax Corp.Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US9757437B2 (en)2004-09-272017-09-12Dyax Corp.Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US10874714B2 (en)2004-10-292020-12-2989Bio Ltd.Method of treating fibroblast growth factor 21 (FGF-21) deficiency
EP3061461A1 (en)2004-10-292016-08-31ratiopharm GmbHRemodeling and glycopegylation of fibroblast growth factor (fgf)
US9200049B2 (en)2004-10-292015-12-01Novo Nordisk A/SRemodeling and glycopegylation of fibroblast growth factor (FGF)
EP2586456A1 (en)2004-10-292013-05-01BioGeneriX AGRemodeling and glycopegylation of fibroblast growth factor (FGF)
US8765883B2 (en)2004-12-212014-07-01Nektar TherapeuticsStabilized polymeric thiol reagents
US8217123B2 (en)2004-12-212012-07-10Nektar TherapeuticsStabilized polymeric thiol reagents
US7851565B2 (en)2004-12-212010-12-14Nektar TherapeuticsStabilized polymeric thiol reagents
US9308274B2 (en)2004-12-212016-04-12Nektar TherapeuticsStabilized polymeric thiol reagents
US8492488B2 (en)2004-12-212013-07-23Nektar TherapeuticsStabilized polymeric thiol reagents
US20110112277A1 (en)*2004-12-212011-05-12Nektar TherapeuticsStabilized Polymeric Thiol Reagents
US20060135586A1 (en)*2004-12-212006-06-22Antoni KozlowskiStabilized polymeric thiol reagents
US7947473B2 (en)2004-12-222011-05-24Ambrx, Inc.Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US20100184140A1 (en)*2004-12-222010-07-22Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US7883866B2 (en)2004-12-222011-02-08Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en)2004-12-222010-12-28Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2284191A2 (en)2004-12-222011-02-16Ambrx, Inc.Process for the preparation of hGH
US7939496B2 (en)2004-12-222011-05-10Ambrx, Inc.Modified human growth horomone polypeptides and their uses
US7816320B2 (en)2004-12-222010-10-19Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8143216B2 (en)2004-12-222012-03-27Ambrx, Inc.Modified human growth hormone
US8178108B2 (en)2004-12-222012-05-15Ambrx, Inc.Methods for expression and purification of recombinant human growth hormone
US8163695B2 (en)2004-12-222012-04-24AmbrxFormulations of human growth hormone comprising a non-naturally encoded amino acid
US20100173380A1 (en)*2004-12-222010-07-08Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US8080391B2 (en)2004-12-222011-12-20Ambrx, Inc.Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7838265B2 (en)2004-12-222010-11-23Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US7846689B2 (en)2004-12-222010-12-07Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US20100167347A1 (en)*2004-12-222010-07-01Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US7959926B2 (en)2004-12-222011-06-14Ambrx, Inc.Methods for expression and purification of recombinant human growth hormone mutants
US20100173379A1 (en)*2004-12-222010-07-08Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US7736872B2 (en)2004-12-222010-06-15Ambrx, Inc.Compositions of aminoacyl-TRNA synthetase and uses thereof
US20060135427A1 (en)*2004-12-222006-06-22Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid
US20100174054A1 (en)*2004-12-222010-07-08Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US8178494B2 (en)2004-12-222012-05-15Ambrx, Inc.Modified human growth hormone formulations with an increased serum half-life
US20110195899A1 (en)*2004-12-222011-08-11Ambrx, Inc.Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid
US7829310B2 (en)2004-12-222010-11-09Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2514757A2 (en)2005-01-102012-10-24BioGeneriX AGGlycopegylated granulocyte colony stimulating factor
US9029331B2 (en)2005-01-102015-05-12Novo Nordisk A/SGlycopegylated granulocyte colony stimulating factor
US9707252B2 (en)2005-02-092017-07-18Covidien LpSynthetic sealants
US20090030451A1 (en)*2005-02-092009-01-29Hadba Ahmad RSynthetic Sealants
US20100196423A1 (en)*2005-02-232010-08-05Bookbinder Louis HSoluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2006091871A1 (en)2005-02-232006-08-31Halozyme Therapeutics, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7846431B2 (en)2005-02-232010-12-07Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7829081B2 (en)2005-02-232010-11-09Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US10588983B2 (en)2005-02-232020-03-17Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP3045472A1 (en)2005-02-232016-07-20Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP3943501A1 (en)2005-02-232022-01-26Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2279756A2 (en)2005-04-052011-02-02Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A.Method for shielding functional sites or epitopes on proteins
EP2314320A2 (en)2005-04-052011-04-27Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.Method for shielding functional sites or epitopes on proteins
EP2386571A2 (en)2005-04-082011-11-16BioGeneriX AGCompositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187546B2 (en)2005-04-082015-11-17Novo Nordisk A/SCompositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8907071B2 (en)2005-04-222014-12-09Amgen Inc.Toxin peptide therapeutic agents
US7833979B2 (en)2005-04-222010-11-16Amgen Inc.Toxin peptide therapeutic agents
US20110045587A1 (en)*2005-04-222011-02-24Amegen Inc.Toxin peptide therapeutic agents
US20070071764A1 (en)*2005-04-222007-03-29Sullivan John KToxin peptide therapeutic agents
US8404809B2 (en)2005-05-252013-03-26Novo Nordisk A/SGlycopegylated factor IX
US20100081791A1 (en)*2005-05-252010-04-01Novo Nordisk A/SGlycopegylated factor ix
EP2975135A1 (en)2005-05-252016-01-20Novo Nordisk A/SGlycopegylated factor IX
US20080255026A1 (en)*2005-05-252008-10-16Glycopegylated Factor 1XGlycopegylated Factor Ix
US9505867B2 (en)2005-05-312016-11-29Ecole Polytechmique Fédérale De LausanneTriblock copolymers for cytoplasmic delivery of gene-based drugs
US20100222407A1 (en)*2005-05-312010-09-02Tatiana SeguraTriblock copolymers for cytoplasmic delivery of gene-based drugs
US20100135959A1 (en)*2005-06-032010-06-03Ambrx, Inc.Human Interferon Molecules and Their Uses
US20080119640A1 (en)*2005-06-032008-05-22Ambrx, Inc.Human Interferon Molecules and Their Uses
US20080132681A1 (en)*2005-06-032008-06-05Ambrx, Inc.Human Interferon Molecules and Their Uses
US8093356B2 (en)2005-06-032012-01-10Ambrx, Inc.Pegylated human interferon polypeptides
US20080108792A1 (en)*2005-06-032008-05-08Ambrx, Inc.Human Interferon Molecules and Their Uses
US9114175B2 (en)2005-08-122015-08-25Amgen Inc.Modified Fc molecules
US10188740B2 (en)2005-08-122019-01-29Amgen Inc.Modified Fc molecules
US11266744B2 (en)2005-08-122022-03-08Amgen Inc.Modified Fc molecules
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
EP2425860A1 (en)2005-08-122012-03-07Amgen Inc.Modified Fc molecules
US7632823B2 (en)2005-08-182009-12-15Ambrx, Inc.Compositions of tRNA and uses thereof
US20080153745A1 (en)*2005-08-182008-06-26Ambrx, In.Compositions of tRNA and uses thereof
US8911967B2 (en)2005-08-192014-12-16Novo Nordisk A/SOne pot desialylation and glycopegylation of therapeutic peptides
US8841439B2 (en)2005-11-032014-09-23Novo Nordisk A/SNucleotide sugar purification using membranes
US20090137736A1 (en)*2005-11-082009-05-28Ambrx, Inc.Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides
US9488660B2 (en)2005-11-162016-11-08Ambrx, Inc.Methods and compositions comprising non-natural amino acids
US20110144307A1 (en)*2005-11-162011-06-16Ambrx, Inc.Methods and Compositions Comprising Non-Natural Amino Acids
US20080317670A1 (en)*2005-12-142008-12-25Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
US20070137573A1 (en)*2005-12-212007-06-21Arnold KholodenkoApparatus for an optimized plasma chamber grounded electrode assembly
US20070196416A1 (en)*2006-01-182007-08-23Quest Pharmaceutical ServicesPharmaceutical compositions with enhanced stability
WO2007084460A2 (en)2006-01-182007-07-26Qps, LlcPharmaceutical compositions with enhanced stability
US8840882B2 (en)2006-06-232014-09-23Quintessence Biosciences, Inc.Modified ribonucleases
US20080025964A1 (en)*2006-06-232008-01-31Quintessence Biosciences, Inc.Modified ribonucleases
WO2007149594A2 (en)2006-06-232007-12-27Quintessence Biosciences, Inc.Modified ribonucleases
US9192656B2 (en)2006-07-172015-11-24Quintessence Biosciences, Inc.Methods and compositions for the treatment of cancer
US8298801B2 (en)2006-07-172012-10-30Quintessence Biosciences, Inc.Methods and compositions for the treatment of cancer
US20080095755A1 (en)*2006-07-172008-04-24Quintessence Biosciences, Inc.Methods and compositions for the treatment of cancer
US9187532B2 (en)2006-07-212015-11-17Novo Nordisk A/SGlycosylation of peptides via O-linked glycosylation sequences
WO2008030558A2 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
US20110207914A1 (en)*2006-09-082011-08-25Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US20100160212A1 (en)*2006-09-082010-06-24Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US20100159586A1 (en)*2006-09-082010-06-24Ambrx, Inc.Hybrid Suppressor tRNA for Vertebrate Cells
US8618257B2 (en)2006-09-082013-12-31Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en)2006-09-082013-04-16Ambrx, Inc.Suppressor tRNA transcription in vertebrate cells
US9133495B2 (en)2006-09-082015-09-15Ambrx, Inc.Hybrid suppressor tRNA for vertebrate cells
US20100159585A1 (en)*2006-09-082010-06-24Ambrx, Inc.Suppressor tRNA Transcription in Vertebrate Cells
US20080113411A1 (en)*2006-09-082008-05-15Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US7919591B2 (en)2006-09-082011-04-05Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US8022186B2 (en)2006-09-082011-09-20Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US20080113412A1 (en)*2006-09-082008-05-15Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US8053560B2 (en)2006-09-082011-11-08Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
EP2548967A2 (en)2006-09-212013-01-23The Regents of The University of CaliforniaAldehyde tags, uses thereof in site-specific protein modification
US8969532B2 (en)2006-10-032015-03-03Novo Nordisk A/SMethods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008060780A2 (en)2006-10-042008-05-22Novo Nordisk A/SGlycerol linked pegylated sugars and glycopeptides
US20090299044A1 (en)*2006-10-252009-12-03Sullivan John KDNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
US7803769B2 (en)2006-10-252010-09-28Amgen Inc.OSK1 peptide analogs and pharmaceutical compositions
US7820623B2 (en)2006-10-252010-10-26Amgen Inc.Conjugated toxin peptide therapeutic agents
US20090305399A1 (en)*2006-10-252009-12-10Sullivan John KDNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression
US8043829B2 (en)2006-10-252011-10-25Amgen Inc.DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
US7825093B2 (en)2006-10-252010-11-02Amgen Inc.Methods of using OSK1 peptide analogs
US7834164B2 (en)2006-10-252010-11-16Amgen Inc.DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression
US20090281028A1 (en)*2006-10-252009-11-12Sullivan John KOSK1 peptide analogs and pharmaceutical compositions
US7910102B2 (en)2006-10-252011-03-22Amgen Inc.Methods of using conjugated toxin peptide therapeutic agents
US8541608B2 (en)2006-11-302013-09-24Nektar TherapeuticsMethod for preparing a polymer conjugate
US20100010194A1 (en)*2006-11-302010-01-14Nektar Therapeutics Al, CorporationMethod for Preparing a Polymer Conjugate
US8937180B2 (en)2006-11-302015-01-20Nektar TherapeuticsMethod for preparing a polymer conjugate
US8354549B2 (en)2006-11-302013-01-15Nektar TherapeuticsMethod for preparing a polymer conjugate
US8685417B2 (en)2006-12-202014-04-01Arkema, Inc.Polymer encapsulation and/or binding
WO2008095063A1 (en)2007-01-312008-08-07Dana-Farber Cancer Institute, Inc.Stabilized p53 peptides and uses thereof
EP2952522A1 (en)2007-01-312015-12-09Dana-Farber Cancer Institute, Inc.Stabilized p53 peptides and uses thereof
US20090227981A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090227689A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US8383365B2 (en)2007-03-302013-02-26Ambrx, Inc.Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US8012931B2 (en)2007-03-302011-09-06Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US9517273B2 (en)2007-03-302016-12-13Ambrx, Inc.Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US20110172401A1 (en)*2007-03-302011-07-14Ambrx, Inc.Modified FGF-21 Polypeptides and Their Uses
US11993637B2 (en)2007-03-302024-05-28Ambrx, Inc.Modified FGF-21 polypeptides with non-naturally encoded amino acids
US9975936B2 (en)2007-03-302018-05-22Ambrx, Inc.Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9079971B2 (en)2007-03-302015-07-14Ambrx, Inc.Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US10961291B2 (en)2007-03-302021-03-30Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US20080255045A1 (en)*2007-03-302008-10-16Ambrx, Inc.Modified FGF-21 Polypeptides and Their Uses
US10377805B2 (en)2007-03-302019-08-13Ambrx, Inc.Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9050304B2 (en)2007-04-032015-06-09Ratiopharm GmbhMethods of treatment using glycopegylated G-CSF
US8961947B2 (en)2007-04-132015-02-24Kuros Biosurgery AgPolymeric tissue sealant
US20080253987A1 (en)*2007-04-132008-10-16Kuros Biosurgery AgPolymeric tissue sealant
US9180222B2 (en)2007-04-132015-11-10Kuros Biosurgery AgPolymeric tissue sealant
US8114630B2 (en)2007-05-022012-02-14Ambrx, Inc.Modified interferon beta polypeptides and their uses
US20090208454A1 (en)*2007-05-022009-08-20Ambrx, Inc.Modified interferon beta polypeptides and their uses
US8420779B2 (en)2007-05-222013-04-16Amgen Inc.Compositions and methods for producing bioactive fusion proteins
EP2738257A1 (en)2007-05-222014-06-04Amgen Inc.Compositions and methods for producing bioactive fusion proteins
US20090118181A1 (en)*2007-05-222009-05-07Walker Kenneth WCompositions and methods for producing bioactive fusion proteins
US9493499B2 (en)2007-06-122016-11-15Novo Nordisk A/SProcess for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US20090000924A1 (en)*2007-06-292009-01-01Harley-Davidson Motor Company Group, Inc.Integrated ignition and key switch
US10251954B2 (en)2007-07-092019-04-09Incept, LlcHydrogel polymeric compositions and methods
US20090252781A1 (en)*2007-07-092009-10-08Incept LlcHydrogel polymeric compositions and methods
US9775906B2 (en)2007-07-092017-10-03Incept LlcHydrogel polymeric compositions and methods
US20090017097A1 (en)*2007-07-092009-01-15Sawhney Amarpreet SHydrogel polymeric compositions and methods
US11324828B2 (en)2007-07-092022-05-10Incept, LlcHydrogel polymeric compositions and methods
US9370485B2 (en)2007-07-092016-06-21Incept, LlcHydrogel polymeric compositions and methods
US9125807B2 (en)2007-07-092015-09-08Incept LlcAdhesive hydrogels for ophthalmic drug delivery
US20110269942A1 (en)*2007-08-092011-11-03Daiichi Sankyo Company, LimitedAntibodies modified with hydrophobic molecule
US8067028B2 (en)2007-08-132011-11-29Confluent Surgical Inc.Drug delivery device
US20090047349A1 (en)*2007-08-132009-02-19Confluent Surgical, Inc.Drug delivery device
US20090075887A1 (en)*2007-08-212009-03-19Genzyme CorporationTreatment with Kallikrein Inhibitors
US8207112B2 (en)2007-08-292012-06-26Biogenerix AgLiquid formulation of G-CSF conjugate
US20110014118A1 (en)*2007-09-212011-01-20Lawrence TamarkinNanotherapeutic colloidal metal compositions and methods
US20090104114A1 (en)*2007-09-212009-04-23Cytimmune Sciences, Inc.Nanotherapeutic Colloidal Metal Compositions and Methods
US20090098101A1 (en)*2007-10-082009-04-16Quintessence Biosciences, Inc.Compositions and methods for ribonuclease-based therapeutics
US8697062B2 (en)2007-10-082014-04-15Quintessence Biosciences, Inc.Compositions and methods for ribonuclease-based therapeutics
US8486663B2 (en)2007-11-082013-07-16Cytlmmune Sciences, Inc.Compositions and methods for generating antibodies
US7960145B2 (en)2007-11-082011-06-14Cytimmune Sciences, Inc.Compositions and methods for generating antibodies
US20090148908A1 (en)*2007-11-082009-06-11Paciotti Giulio FCompositions and methods for generating antibodies
US8946148B2 (en)2007-11-202015-02-03Ambrx, Inc.Modified insulin polypeptides and their uses
EP2930182A1 (en)2007-11-202015-10-14Ambrx, Inc.Modified insulin polypeptides and their uses
US20100298212A1 (en)*2007-11-202010-11-25Ambrx, Inc.Modified Insulin Polypeptides and Their Uses
WO2009067636A2 (en)2007-11-202009-05-28Ambrx, Inc.Modified insulin polypeptides and their uses
EP3103880A1 (en)2008-02-082016-12-14Ambrx, Inc.Modified leptin polypeptides and their uses
US9938333B2 (en)2008-02-082018-04-10Ambrx, Inc.Modified leptin polypeptides and their uses
US9150848B2 (en)2008-02-272015-10-06Novo Nordisk A/SConjugated factor VIII molecules
US9833498B2 (en)2008-03-062017-12-05Halozyme, Inc.Methods of treatment of collagen-mediated diseases and conditions
US9775889B2 (en)2008-03-062017-10-03Halozyme, Inc.Methods of treatment of cellulite
EP2662090A1 (en)2008-04-142013-11-13Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP3192525A1 (en)2008-04-142017-07-19Halozyme, Inc.Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions
US10328130B2 (en)2008-04-142019-06-25Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8318154B2 (en)2008-04-282012-11-27Halozyme, Inc.Super fast-acting insulin compositions
EP2705850A2 (en)2008-04-282014-03-12Halozyme, Inc.Super fast-acting insulin compositions
US8618333B2 (en)2008-07-212013-12-31Polytherics LimitedReagents and method for conjugating biological molecules
US8969626B2 (en)2008-07-212015-03-03Polytherics LimitedReagents and method for conjugating biological molecules
US20110136723A1 (en)*2008-07-212011-06-09Polytherics LimitedNovel reagents and method for conjugating biological molecules
US9896412B2 (en)2008-07-212018-02-20Polytherics LimitedReagents and method for conjugating biological molecules
WO2010011735A2 (en)2008-07-232010-01-28Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
EP3225248A1 (en)2008-07-232017-10-04Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
US20100035812A1 (en)*2008-07-232010-02-11Ambrx, Inc.Modified Bovine G-CSF Polypeptides And Their Uses
US10138283B2 (en)2008-07-232018-11-27Ambrx, Inc.Modified bovine G-CSF polypeptides and their uses
US20110195483A1 (en)*2008-09-262011-08-11Ambrx, Inc.Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines
US9121025B2 (en)2008-09-262015-09-01Ambrx, Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US20100093608A1 (en)*2008-09-262010-04-15Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en)2008-09-262015-09-01Ambrx, Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US9644014B2 (en)2008-09-262017-05-09Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US10428333B2 (en)2008-09-262019-10-01Ambrx Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
EP3216800A1 (en)2008-09-262017-09-13Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US8278418B2 (en)2008-09-262012-10-02Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US8569233B2 (en)2008-09-262013-10-29Eli Lilly And CompanyModified animal erythropoietin polypeptides and their uses
US9156899B2 (en)2008-09-262015-10-13Eli Lilly And CompanyModified animal erythropoietin polypeptides and their uses
US8029782B2 (en)2008-10-012011-10-04Quintessence Biosciences, Inc.Therapeutic ribonucleases
US9579365B2 (en)2008-10-012017-02-28Quintessence Biosciences, Inc.Therapeutic ribonucleases
US8216567B2 (en)2008-10-012012-07-10Quintessence Biosciences, Inc.Therapeutic ribonucleases
US8628768B2 (en)2008-10-012014-01-14Quintessence Biosciences, Inc.Therapeutic ribonucleases
US9006407B2 (en)2008-10-012015-04-14Quintessence Biosciences, Inc.Therapeutic ribonucleases
US9271929B2 (en)2008-11-252016-03-01École Polytechnique Fédérale De Lausanne (Epfl)Block copolymers and uses thereof
US10335499B2 (en)2008-11-252019-07-02École Polytechnique Fédérale De Lausanne (Epfl)Block copolymers and uses thereof
US9284543B2 (en)2008-12-092016-03-15Halozyme, Inc.Neutral active soluble truncated PH20 polypeptides and uses thereof
US8927249B2 (en)2008-12-092015-01-06Halozyme, Inc.Extended soluble PH20 polypeptides and uses thereof
EP3037529A1 (en)2008-12-092016-06-29Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
WO2010077297A1 (en)2008-12-092010-07-08Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
US20100183625A1 (en)*2009-01-062010-07-22Dyax Corp.Treatment of Mucositis with Kallikrein Inhibitors
US8637454B2 (en)2009-01-062014-01-28Dyax Corp.Treatment of mucositis with kallikrein inhibitors
US8563027B2 (en)2009-02-122013-10-22Incept, LlcDrug delivery through hydrogel plugs
US8409606B2 (en)2009-02-122013-04-02Incept, LlcDrug delivery through hydrogel plugs
US9005598B2 (en)2009-03-042015-04-14Polytherics LimitedConjugated proteins and peptides
US9415115B2 (en)2009-03-042016-08-16Polytherics LimitedConjugated proteins and peptides
WO2010144629A1 (en)2009-06-092010-12-16Prolong Pharmaceuticals, LLCHemoglobin compositions
EP3266463A1 (en)2009-06-092018-01-10Prolong Pharmaceuticals, LLCHemoglobin compositions
EP2550958A1 (en)2009-08-052013-01-30Pieris AGControlled release formulations of lipocalin muteins
WO2011015634A2 (en)2009-08-052011-02-10Pieris AgControlled release formulations of lipocalin muteins
US9084743B2 (en)2009-09-172015-07-21Baxter International Inc.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011034604A2 (en)2009-09-172011-03-24Baxter Healthcare, S.A.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
EP2805964A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified porcine somatotropin polypeptides and their uses
US20110200611A1 (en)*2010-01-062011-08-18Dyax Corp.Plasma kallikrein binding proteins
US8822653B2 (en)2010-01-062014-09-02Dyax Corp.Plasma kallikrein binding proteins
US10336832B2 (en)2010-01-062019-07-02Dyax Corp.Methods of inhibiting plasma kallikrein in edema patient
US11505620B2 (en)2010-01-062022-11-22Takeda Pharmaceutical Company LimitedMethods of detecting plasma kallikrein
WO2012012300A2 (en)2010-07-202012-01-26Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US9878046B2 (en)2010-07-202018-01-30Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US10265410B2 (en)2010-07-202019-04-23Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US9962450B2 (en)2010-08-172018-05-08Ambrx, Inc.Method of treating heart failure with modified relaxin polypeptides
US8735539B2 (en)2010-08-172014-05-27Ambrx, Inc.Relaxin polypeptides comprising non-naturally encoded amino acids
US10702588B2 (en)2010-08-172020-07-07Ambrx, Inc.Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US9452222B2 (en)2010-08-172016-09-27Ambrx, Inc.Nucleic acids encoding modified relaxin polypeptides
US11311605B2 (en)2010-08-172022-04-26Ambrx, Inc.Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
WO2012024452A2 (en)2010-08-172012-02-23Ambrx, Inc.Modified relaxin polypeptides and their uses
EP4302783A2 (en)2010-08-172024-01-10Ambrx, Inc.Modified relaxin polypeptides and their uses
US10253083B2 (en)2010-08-172019-04-09Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
US10751391B2 (en)2010-08-172020-08-25Ambrx, Inc.Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US11439710B2 (en)2010-08-172022-09-13Ambrx, Inc.Nucleic acids encoding modified relaxin polypeptides
US11786578B2 (en)2010-08-172023-10-17Ambrx, Inc.Modified relaxin polypeptides and their uses
US9567386B2 (en)2010-08-172017-02-14Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
US8961501B2 (en)2010-09-172015-02-24Incept, LlcMethod for applying flowable hydrogels to a cornea
US11273202B2 (en)2010-09-232022-03-15Elanco Us Inc.Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012065181A2 (en)2010-11-122012-05-18Dana Farber Cancer Institute, Inc.Cancer therapies and diagnostics
US11401346B2 (en)2011-01-062022-08-02Takeda Pharmaceutical Company LimitedNucleic acids encoding plasma kallikrein binding proteins
US10370453B2 (en)2011-01-062019-08-06Dyax Corp.Plasma kallikrein binding proteins
US9266964B2 (en)2011-01-062016-02-23Dyax Corp.Method of treating hereditary angioedema using plasma kallikrein binding antibodies
EP2907504A1 (en)2011-02-082015-08-19Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012109387A1 (en)2011-02-082012-08-16Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US9333244B2 (en)2011-02-082016-05-10Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012125973A2 (en)2011-03-162012-09-20Amgen Inc.Potent and selective inhibitors of nav1.3 and nav1.7
WO2012174478A2 (en)2011-06-172012-12-20Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
US9993529B2 (en)2011-06-172018-06-12Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en)2011-06-172012-12-20Halozyme, Inc.Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
WO2013006706A1 (en)2011-07-052013-01-10Bioasis Technologies Inc.P97-antibody conjugates and methods of use
EP3088005A1 (en)2011-07-052016-11-02biOasis Technologies IncP97-antibody conjugates
US10226417B2 (en)2011-09-162019-03-12Peter JarrettDrug delivery systems and applications
WO2013040501A1 (en)2011-09-162013-03-21Pharmathene, Inc.Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
EP2915542A1 (en)2011-10-242015-09-09Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2013063155A2 (en)2011-10-242013-05-02Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US8846034B2 (en)2011-10-242014-09-30Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US9458442B2 (en)2011-10-242016-10-04Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US10905765B2 (en)2011-12-052021-02-02Incept, LlcMedical organogel processes and compositions
US11890343B2 (en)2011-12-052024-02-06Incept, LlcMedical organogel processes and compositions
US9205150B2 (en)2011-12-052015-12-08Incept, LlcMedical organogel processes and compositions
US10077290B2 (en)2011-12-292018-09-18Dana-Farber Cancer Institute, Inc.Stabilized antiviral fusion helices
WO2013102211A2 (en)2011-12-292013-07-04Walensky Loren DStabilized antiviral fusion helices
US12054758B2 (en)2011-12-302024-08-06Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US11066656B2 (en)2011-12-302021-07-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12123035B2 (en)2011-12-302024-10-22Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US10865400B2 (en)2011-12-302020-12-15Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12110520B2 (en)2011-12-302024-10-08Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12018298B2 (en)2011-12-302024-06-25Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
EP3130347A1 (en)2011-12-302017-02-15Halozyme, Inc.Ph20 polypeptide variants, formulations and uses thereof
US12037618B2 (en)2011-12-302024-07-16Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12195773B2 (en)2011-12-302025-01-14Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12104185B2 (en)2011-12-302024-10-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12371685B2 (en)2011-12-302025-07-29Halozyme, Inc.PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
US12049652B2 (en)2011-12-302024-07-30Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12264345B1 (en)2011-12-302025-04-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12060590B2 (en)2011-12-302024-08-13Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12077791B2 (en)2011-12-302024-09-03Halozyme, Inc.PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof
US12152262B2 (en)2011-12-302024-11-26Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US11041149B2 (en)2011-12-302021-06-22Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US11952600B2 (en)2011-12-302024-04-09Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US9447401B2 (en)2011-12-302016-09-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12104184B2 (en)2011-12-302024-10-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12091692B2 (en)2011-12-302024-09-17Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US9885072B2 (en)2012-03-302018-02-06The Board Of Regents Of The University Of OklahomaHigh molecular weight heparosan polymers and methods of production of use thereof
US8980608B2 (en)2012-03-302015-03-17The Board Of Regents Of The University Of OklahomaHigh molecular weight heparosan polymers and methods of production and use thereof
US10392642B2 (en)2012-03-302019-08-27The Board Of Regents Of The University Of OklahomaHigh molecular weight heparosan polymers and methods of production and use thereof
US10137104B2 (en)2012-04-042018-11-27Halozyme, Inc.Combination therapy with an anti-hyaluronan agent and therapeutic agent
WO2013151774A1 (en)2012-04-042013-10-10Halozyme, Inc.Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US9913822B2 (en)2012-04-042018-03-13Halozyme, Inc.Combination therapy with an anti-hyaluronan agent and therapeutic agent
EP3505534A1 (en)2012-06-082019-07-03Sutro Biopharma, Inc.Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en)2012-06-082013-12-12Sutro Biopharma, Inc.Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en)2012-06-262017-03-01Sutro Biopharma, Inc.Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014022515A1 (en)2012-07-312014-02-06Bioasis Technologies, Inc.Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US9395468B2 (en)2012-08-272016-07-19Ocular Dynamics, LlcContact lens with a hydrophilic layer
US11181754B2 (en)2012-08-272021-11-23Tangible Science, LlcContact lens with a hydrophilic layer
US10451896B2 (en)2012-08-272019-10-22Tangible Science, LlcContact lens with a hydrophilic layer
EP4074728A1 (en)2012-08-312022-10-19Sutro Biopharma, Inc.Modified peptides comprising an azido group
WO2014036492A1 (en)2012-08-312014-03-06Sutro Biopharma, Inc.Modified amino acids comprising an azido group
EP3584255A1 (en)2012-08-312019-12-25Sutro Biopharma, Inc.Modified amino acids comprising an azido group
US9278124B2 (en)2012-10-162016-03-08Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014062856A1 (en)2012-10-162014-04-24Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9579390B2 (en)2012-11-122017-02-28Redwood Bioscience, Inc.Compounds and methods for producing a conjugate
US10314919B2 (en)2012-11-162019-06-11Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
US11426465B2 (en)2012-11-162022-08-30Redwiid Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
US9310374B2 (en)2012-11-162016-04-12Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
US9605078B2 (en)2012-11-162017-03-28The Regents Of The University Of CaliforniaPictet-Spengler ligation for protein chemical modification
US10888623B2 (en)2012-11-162021-01-12Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
US9833515B2 (en)2012-11-162017-12-05Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
EP3907237A1 (en)2012-12-202021-11-10Amgen Inc.Apj receptor agonists and uses thereof
WO2014099984A1 (en)2012-12-202014-06-26Amgen Inc.Apj receptor agonists and uses thereof
WO2014165277A2 (en)2013-03-122014-10-09Amgen Inc.POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2014160438A1 (en)2013-03-132014-10-02Bioasis Technologies Inc.Fragments of p97 and uses thereof
EP3572422A1 (en)2013-03-152019-11-27Dana-Farber Cancer Institute, Inc.Bh4 stabilized peptides and uses thereof
WO2014144148A1 (en)2013-03-152014-09-18Dana-Farber Cancer Institute, Inc.Stabilized sos1 peptides
WO2014144768A2 (en)2013-03-152014-09-18Dana-Farber Cancer Institute, Inc.Bh4 stabilized peptides and uses thereof
US11046739B2 (en)2013-03-152021-06-29Dana-Farber Cancer Institute, Inc.BH4 stabilized peptides and uses thereof
US10106590B2 (en)2013-03-152018-10-23Dana-Farber Cancer Institute, Inc.BH4 stabilized peptides and uses thereof
US10308926B2 (en)2013-03-152019-06-04Dana-Farber Cancer Institute, Inc.Stablized EZH2 peptides
US10087215B2 (en)2013-03-152018-10-02Dana-Farber Cancer Institute, Inc.Stabilized SOS1 peptides
WO2014151369A2 (en)2013-03-152014-09-25Dana-Farber Cancer Institute, Inc.Stabilized ezh2 peptides
WO2015003167A1 (en)2013-07-032015-01-08Halozyme, Inc.Thermally stable ph20 hyaluronidase variants and uses thereof
EP3336103A1 (en)2013-07-102018-06-20Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015006555A2 (en)2013-07-102015-01-15Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US10711106B2 (en)2013-07-252020-07-14The University Of ChicagoHigh aspect ratio nanofibril materials
WO2015031673A2 (en)2013-08-282015-03-05Bioasis Technologies Inc.Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054658A1 (en)2013-10-112015-04-16Sutro Biopharma, Inc.Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US11433628B2 (en)2013-11-152022-09-06Tangible Science, Inc.Contact lens with a hydrophilic layer
US10330951B2 (en)2013-11-152019-06-25Tangible Science, LlcContact lens with a hydrophilic layer
US9310627B2 (en)2013-11-152016-04-12Ocular Dynamics, LlcContact lens with a hydrophilic layer
WO2015081282A1 (en)2013-11-272015-06-04Redwood Bioscience, Inc.Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP4592275A2 (en)2013-11-272025-07-30Redwood Bioscience, Inc.Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US11046785B2 (en)2014-03-272021-06-29Takeda Pharmaceutical Company LimitedCompositions and methods for treatment of diabetic macular edema
US12084515B2 (en)2014-03-272024-09-10Takeda Pharmaceutical Company LimitedCompositions and methods for treatment of diabetic macular edema
US10358636B2 (en)2014-05-142019-07-23Stealth Biologics, LlcDeimmunized lysostaphin and methods of use
US12104186B2 (en)2014-05-142024-10-01Insmed IncorporatedDeimmunized lysostaphin and methods of use
WO2015175774A1 (en)2014-05-142015-11-19Trustees Of Dartmouth CollegeDeimmunized lysostaphin and methods of use
US11091749B2 (en)2014-05-142021-08-17Trustees Of Dartmouth CollegeDeimmunized lysostaphin and methods of use
US10941182B2 (en)2014-06-102021-03-09Amgen Inc.Apelin polypeptides
US11807693B2 (en)2014-06-102023-11-07Amgen Inc.Apelin polypeptides
EP4257152A2 (en)2014-06-102023-10-11Amgen Inc.Apelin polypeptides
WO2015191781A2 (en)2014-06-102015-12-17Amgen Inc.Apelin polypeptides
EP3674314A2 (en)2014-06-102020-07-01Amgen, IncApelin polypeptides
WO2016033555A1 (en)2014-08-282016-03-03Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US11414489B2 (en)2014-08-282022-08-16Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
WO2016061286A2 (en)2014-10-142016-04-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US11584923B2 (en)2014-10-142023-02-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US9969998B2 (en)2014-10-142018-05-15Halozyme, Inc.Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US9434778B2 (en)2014-10-242016-09-06Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9631004B2 (en)2014-10-242017-04-25Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US12247058B2 (en)2014-10-242025-03-11Bristol-Myers Squibb CompanyNucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof
US10189883B2 (en)2014-10-242019-01-29Bristol-Myers Squibb CompanyTherapeutic uses of modified FGF-21 polypeptides
US11248031B2 (en)2014-10-242022-02-15Bristol-Myers Squibb CompanyMethods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10377806B2 (en)2014-10-242019-08-13Bristol-Myers Squibb CompanyMethods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10525170B2 (en)*2014-12-092020-01-07Tangible Science, LlcMedical device coating with a biocompatible layer
US11260150B2 (en)2014-12-092022-03-01Tangible Science, Inc.Medical device coating with a biocompatible layer
US20170360994A1 (en)*2014-12-092017-12-21Tangible Science, LlcMedical device coating with a biocompatible layer
US11142554B2 (en)2015-03-182021-10-12Massachusetts Institute Of TechnologySelective Mcl-1 binding peptides
US10464975B2 (en)2015-07-022019-11-05Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides
US11078246B2 (en)2015-08-282021-08-03Dana-Farber Cancer Institute, Inc.Peptides binding to Bfl-1
US12102689B2 (en)2015-11-092024-10-01R.P. Scherer Technologies, LlcAnti-CD22 antibody-maytansine conjugates and methods of use thereof
US11286307B2 (en)2015-12-112022-03-29Takeda Pharmaceutical Company LimitedPlasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US12391733B2 (en)2016-02-292025-08-19Dana-Farber Cancer Institute, Inc.Stapled intracellular-targeting antimicrobial peptides to treat infection
US11945846B2 (en)2016-02-292024-04-02Dana-Farber Cancer Institute, Inc.Stapled intracellular-targeting antimicrobial peptides to treat infection
US10421785B2 (en)2016-04-112019-09-24Bar-Ilan UniversityDelta receptor agonist peptides and use thereof
US12312437B2 (en)2016-04-152025-05-27Beckman Coulter, Inc.Photoactive macromolecules and uses thereof
US11198715B2 (en)2016-07-222021-12-14Massachusetts Institute Of TechnologySelective Bfl-1 peptides
US11466064B2 (en)2016-08-262022-10-11Dana-Farber Cancer Institute, Inc.Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018039545A2 (en)2016-08-262018-03-01Dana-Farber Cancer Institute, Inc.Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
US12344643B2 (en)2016-12-072025-07-01The University Of ChicagoCompositions and methods for inhibition of FOXP3
US12097241B2 (en)2017-02-082024-09-24Bristol-Myers Squibb CompanyMethods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
US11185570B2 (en)2017-02-082021-11-30Bristol-Myers Squibb CompanyMethod of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US12097242B2 (en)2017-02-082024-09-24Bristol-Myers Squibb CompanyTreatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
US10266578B2 (en)2017-02-082019-04-23Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11364281B2 (en)2017-02-082022-06-21Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
WO2018170299A1 (en)2017-03-152018-09-20The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesInhibitors of prokaryotic gene transcription and uses thereof
WO2018237201A1 (en)2017-06-222018-12-27Catalyst Biosciences, Inc. MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE
US12173337B2 (en)2017-06-222024-12-24Vertex Pharmaceuticals, IncorporatedNucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US11401513B2 (en)2017-06-222022-08-02Catalyst Biosciences, Inc.Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US11807882B2 (en)2017-06-222023-11-07Vertex Pharmaceuticals IncorporatedModified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US10781435B2 (en)2017-06-222020-09-22Catalyst Biosciences, Inc.Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US10954501B2 (en)2017-06-222021-03-23Catalyst Biosciences, Inc.Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019018499A2 (en)2017-07-192019-01-24Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
US11325955B2 (en)2017-07-192022-05-10Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019118719A1 (en)2017-12-152019-06-20Dana-Farber Cancer Institute, Inc.Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
WO2019118893A1 (en)2017-12-152019-06-20Dana-Farber Cancer Institute, Inc.Stabilized peptide-mediated targeted protein degradation
US11834520B2 (en)2017-12-152023-12-05Dana-Farber Cancer Institute, Inc.Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
WO2019133399A1 (en)2017-12-262019-07-04Becton, Dickinson And CompanyDeep ultraviolet-excitable water-solvated polymeric dyes
US11952432B2 (en)2018-02-072024-04-09Dana-Farber Cancer Institute, Inc.Cell-permeable stapled peptide modules for cellular delivery
WO2019157131A1 (en)2018-02-072019-08-15Dana-Farber Cancer Institute, Inc.Cell-permeable stapled peptide modules for cellular delivery
WO2019178313A1 (en)2018-03-142019-09-19Dana-Farber Cancer Institute, Inc.Stabilized peptides for biomarker detection
WO2019191482A1 (en)2018-03-302019-10-03Becton, Dickinson And CompanyWater-soluble polymeric dyes having pendant chromophores
WO2019222435A1 (en)2018-05-162019-11-21Halozyme, Inc.Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020023300A1 (en)2018-07-222020-01-30Bioasis Technologies, Inc.Treatment of lymmphatic metastases
US12049485B2 (en)2018-09-112024-07-30Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
EP4389145A2 (en)2018-09-112024-06-26Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
WO2020056066A1 (en)2018-09-112020-03-19Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
US11286299B2 (en)2018-09-172022-03-29Massachusetts Institute Of TechnologyPeptides selective for Bcl-2 family proteins
WO2020082057A1 (en)2018-10-192020-04-23Ambrx, Inc.Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020131871A1 (en)*2018-12-192020-06-25Tangible Science, Inc.Systems and methods of treating a hydrogel-coated medical device
US11613744B2 (en)2018-12-282023-03-28Vertex Pharmaceuticals IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
US12331334B2 (en)2018-12-282025-06-17Vertex Pharmaceuticals, IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
WO2020140101A1 (en)2018-12-282020-07-02Catalyst Biosciences, Inc.Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020168017A1 (en)2019-02-122020-08-20Ambrx, Inc.Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2020215005A1 (en)2019-04-182020-10-22Dana-Farber Cancer Institute, Inc.Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
US12358960B2 (en)2019-04-182025-07-15Dana-Farber Cancer Institute, Inc.Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
WO2021126827A1 (en)2019-12-162021-06-24Dana-Farber Cancer Institute, Inc.Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en)2019-12-202021-06-24Dana-Farber Cancer Institute, Inc.Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
WO2021178714A2 (en)2020-03-042021-09-10Dana-Farber Cancer Institute, Inc.ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
WO2021183832A1 (en)2020-03-112021-09-16Ambrx, Inc.Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021216845A1 (en)2020-04-222021-10-28Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
WO2021222243A2 (en)2020-04-272021-11-04Dana-Farber Cancer Institute, Inc.Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
WO2021236526A1 (en)2020-05-182021-11-25Bioasis Technologies, Inc.Compositions and methods for treating lewy body dementia
WO2021255524A1 (en)2020-06-172021-12-23Bioasis Technologies, Inc.Compositions and methods for treating frontotemporal dementia
WO2022040596A1 (en)2020-08-202022-02-24Ambrx, Inc.Antibody-tlr agonist conjugates, methods and uses thereof
WO2022081827A1 (en)2020-10-142022-04-21Dana-Farber Cancer Institute, Inc.Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2022098848A1 (en)2020-11-052022-05-12Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ebolavirus peptides and uses thereof
WO2022212899A1 (en)2021-04-032022-10-06Ambrx, Inc.Anti-her2 antibody-drug conjugates and uses thereof
WO2023039474A1 (en)2021-09-082023-03-16Dana-Farber Cancer Institute, Inc.Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
EP4155349A1 (en)2021-09-242023-03-29Becton, Dickinson and CompanyWater-soluble yellow green absorbing dyes
WO2023215784A1 (en)2022-05-042023-11-09Dana-Farber Cancer Institute, Inc.Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2024007016A2 (en)2022-07-012024-01-04Beckman Coulter, Inc.Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en)2022-08-262024-02-29Beckman Coulter, Inc.Dhnt monomers and polymer dyes with modified photophysical properties
US12441775B2 (en)2022-08-292025-10-14Dana-Farber Cancer Institute, Inc.BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2024196805A1 (en)2023-03-172024-09-26Beckman Coulter, Inc.Benzothienopyrrole cyanine dyes
WO2025064842A1 (en)2023-09-212025-03-27Beckman Coulter, Inc.Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry

Also Published As

Publication numberPublication date
US20050209416A1 (en)2005-09-22
US7214366B2 (en)2007-05-08
EE03448B1 (en)2001-06-15
KR960705869A (en)1996-11-08
FI117441B (en)2006-10-13
AU687937B2 (en)1998-03-05
PL180149B1 (en)2000-12-29
CA2176203C (en)2003-06-10
WO1995013312A1 (en)1995-05-18
SK284527B6 (en)2005-05-05
RU2176253C2 (en)2001-11-27
CN1137280A (en)1996-12-04
RO121855B1 (en)2008-06-30
US6610281B2 (en)2003-08-26
US20040037801A1 (en)2004-02-26
NZ276313A (en)1997-04-24
PL314298A1 (en)1996-09-02
AU1054895A (en)1995-05-29
FI962004L (en)1996-05-10
DK0728155T3 (en)2002-07-29
CZ295640B6 (en)2005-09-14
EE9600128A (en)1997-04-15
EP0728155B1 (en)2002-04-03
JPH09508926A (en)1997-09-09
BG100568A (en)1996-12-31
HK1042312A1 (en)2002-08-09
US5900461A (en)1999-05-04
NO961918D0 (en)1996-05-10
US5739208A (en)1998-04-14
CA2176203A1 (en)1995-05-18
BG63399B1 (en)2001-12-29
NO315377B1 (en)2003-08-25
EP0728155A1 (en)1996-08-28
SK60896A3 (en)1997-04-09
HU225649B1 (en)2007-05-29
DE69430317D1 (en)2002-05-08
EP1176160A3 (en)2004-03-03
CZ137596A3 (en)1996-10-16
UA58481C2 (en)2003-08-15
HU9601253D0 (en)1996-07-29
US6894025B2 (en)2005-05-17
HUP9601253A2 (en)2001-06-28
ES2173943T3 (en)2002-11-01
FI962004A0 (en)1996-05-10
DE69430317T2 (en)2002-10-02
CN1085689C (en)2002-05-29
ATE215577T1 (en)2002-04-15
BR9408048A (en)1996-12-24
NO961918L (en)1996-07-12
KR100225746B1 (en)1999-10-15
RO118434B1 (en)2003-05-30
US20020150548A1 (en)2002-10-17
EP1176160A2 (en)2002-01-30
JP3114998B2 (en)2000-12-04

Similar Documents

PublicationPublication DateTitle
US5446090A (en)Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
KR100807141B1 (en) Synthesis of High Molecular Weight Nonpeptidic Polymer Derivatives
US6624246B2 (en)Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
JP4961025B2 (en) Non-antigenic branched polymer conjugate
ES2831379T3 (en) Polymeric derivatives for selective protein modification
KR20020074459A (en)Sterically hindered derivatives of water soluble polymers
HK1132001A (en)Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:SHEARWATER POLYMERS, INC., ALABAMA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, J. MILTON;REEL/FRAME:006850/0117

Effective date:19940124

STCFInformation on status: patent grant

Free format text:PATENTED CASE

CCCertificate of correction
FPAYFee payment

Year of fee payment:4

ASAssignment

Owner name:SHEARWATER CORPORATION, ALABAMA

Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011295/0671

Effective date:20000927

FEPPFee payment procedure

Free format text:PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAYFee payment

Year of fee payment:8

ASAssignment

Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA

Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564

Effective date:20021202

FPAYFee payment

Year of fee payment:12

ASAssignment

Owner name:NEKTAR THERAPEUTICS, CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731

Owner name:NEKTAR THERAPEUTICS,CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731

ASAssignment

Owner name:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATE

Free format text:GRANT OF SECURITY INTEREST;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:028571/0141

Effective date:20120711

Owner name:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, NEW YORK

Free format text:GRANT OF SECURITY INTEREST;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:028571/0141

Effective date:20120711

ASAssignment

Owner name:NEKTAR THERAPEUTICS, CALIFORNIA

Free format text:RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141;ASSIGNOR:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT;REEL/FRAME:036866/0700

Effective date:20151005


[8]ページ先頭

©2009-2025 Movatter.jp